<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cerebrolysin for vascular dementia - Cui, S - 2019 | Cochrane Library</title> <meta content="Cerebrolysin for vascular dementia - Cui, S - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cerebrolysin for vascular dementia - Cui, S - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008900.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Cerebrolysin for vascular dementia" name="citation_title"/> <meta content="Shuhui Cui" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Ning Chen" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Mi Yang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Jian Guo" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Muke Zhou" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cairong Zhu" name="citation_author"/> <meta content="School of Public Health, Sichuan University" name="citation_author_institution"/> <meta content="Li He" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="heli2003new@126.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD008900.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/11/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amino Acids [adverse effects, *therapeutic use]; Cognition [drug effects]; Cost of Illness; Dementia, Vascular [*drug therapy, psychology]; Nootropic Agents [*therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008900.pub3&amp;doi=10.1002/14651858.CD008900.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WbpyPs9C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008900\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008900\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa","fr","hr","ko","ms","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008900.pub3",title:"Cerebrolysin for vascular dementia",firstPublishedDate:"Nov 11, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008900.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008900.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008900.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008900.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008900.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008900.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008900.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008900.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008900.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008900.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5095 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008900.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0033"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0034"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/appendices#CD008900-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/table_n/CD008900StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/table_n/CD008900StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cerebrolysin for vascular dementia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0002">Shuhui Cui</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0003">Ning Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0004">Mi Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0005">Jian Guo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0006">Muke Zhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0007">Cairong Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information#CD008900-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Li He</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information/en#CD008900-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 November 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008900.pub3">https://doi.org/10.1002/14651858.CD008900.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008900-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008900-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008900-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008900-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008900-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008900-abs-0009">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008900-abs-0001" lang="en"> <section id="CD008900-sec-0001"> <h3 class="title" id="CD008900-sec-0001">Background</h3> <p>Although vascular dementia is the second most common cause of dementia globally, evidence‐based treatments are still lacking. Cerebrolysin is a porcine brain‐derived preparation that is said to have neurotrophic and neuroprotective activity. In many parts of the world Cerebrolysin, given as a series of daily intravenous infusions, is used as a potential intervention for vascular dementia. A previous Cochrane Review on Cerebrolysin in vascular dementia yielded inconsistent results. We wished to update the review to add new studies from the international literature and employ contemporary methods for appraising the strength of the evidence. </p> <p>This is the first update of a review first published in 2013.</p> </section> <section id="CD008900-sec-0002"> <h3 class="title" id="CD008900-sec-0002">Objectives</h3> <p>Primary: to assess the effect of Cerebrolysin on cognitive function, global function, and all‐cause mortality in people living with vascular dementia. </p> <p>Secondary: to assess the adverse effects of Cerebrolysin and to assess the effect of Cerebrolysin on quality of life and caregiver burden. </p> </section> <section id="CD008900-sec-0003"> <h3 class="title" id="CD008900-sec-0003">Search methods</h3> <p>We searched ALOIS, MEDLINE, Embase, PsycINFO, CINAHL, ISI Web of Knowledge, LILACS, the Cochrane Library, ClinicalTrials.gov, and the WHO ICTRP on 16 June 2017, 9 May 2018, and 9 May 2019. We expanded the search by adding four Chinese databases, searched from 1 January 2012 to 19 May 2019. We checked bibliographies of relevant papers identified and contacted pharmaceutical companies, trial authors, and experts in the field to identify any additional published or unpublished data. </p> </section> <section id="CD008900-sec-0004"> <h3 class="title" id="CD008900-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials of Cerebrolysin used in people living with vascular dementia. We applied no language restriction. </p> </section> <section id="CD008900-sec-0005"> <h3 class="title" id="CD008900-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion and evaluated their methodological quality. Data were extracted and analysed using mean differences (MDs) or standardised mean differences (SMDs) with 95% confidence intervals (95% CI) for continuous outcomes. We reported dichotomous outcomes as risk ratio (RR) with 95% CI. We assessed the strength of the available evidence using the GRADE approach. </p> </section> <section id="CD008900-sec-0006"> <h3 class="title" id="CD008900-sec-0006">Main results</h3> <p>We identified six randomised controlled trials with a total of 597 participants that were eligible for inclusion in the 2013 review. No new studies were eligible for inclusion in this update. Participants in the included studies, where dementia severity was reported, had mild to moderate severity of vascular dementia (four trials). The included studies tested varying doses and duration of Cerebrolysin treatment. Follow‐up ranged from 15 days to three years. Five of included studies were conducted in China (three studies), Russia (one study), and Romania (one study), while relevant information of other study was unclear. Where details of funding were available, all studies were supported by the pharmaceutical industry (three studies). </p> <p>Cognitive function was measured using the Mini‐Mental State Examination (MMSE) or Alzheimer's Disease Assessment Scale Cognitive Subpart, extended version (ADAS‐cog+). Combining the MMSE and ADAS‐cog+ data (three studies, 420 people), there was a beneficial effect of Cerebrolysin (SMD 0.36, 95% CI 0.13 to 0.58; very low‐quality evidence). </p> <p>Global function was measured by Clinician's Interview‐Based Impression of Change plus Caregiver Input (CIBIC+) or Investigator's Clinical Global Impression (CGI). We assessed response rates on these measures (the proportion of participants with a CIBIC+ score of &lt; 3; or at least moderate improvement of the CGI rating at the last visit). There was a beneficial effect of Cerebrolysin (two studies, 379 participants, RR 2.69, 95% CI 1.82 to 3.98; very low‐quality evidence). </p> <p>Only one trial described mortality and reported no deaths. Four studies reported adverse events; data from two studies (379 people) were in a format that permitted meta‐analysis, and there was no difference in rates of adverse effects (RR 0.91, 95% CI 0.29 to 2.85; very low‐quality evidence). No studies reported on quality of life or caregiver burden. </p> </section> <section id="CD008900-sec-0007"> <h3 class="title" id="CD008900-sec-0007">Authors' conclusions</h3> <p>Courses of intravenous Cerebrolysin improved cognition and general function in people living with vascular dementia, with no suggestion of adverse effects. However, these data are not definitive. Our analyses were limited by heterogeneity, and the included papers had high risk of bias. If there are benefits of Cerebrolysin, the effects may be too small to be clinically meaningful. There have been no new studies of Cerebrolysin in vascular dementia since the last Cochrane Review. Cerebrolysin continues to be used and promoted as a treatment for vascular dementia, but the supporting evidence base is weak. Adequately powered, methodologically robust trials are needed to properly assess the effects of Cerebrolysin in vascular dementia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008900-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008900-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008900-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008900-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008900-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008900-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008900-abs-0014">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008900-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008900-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008900-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008900-abs-0004" lang="en"> <h3>Cerebrolysin for vascular dementia</h3> <p><b>Background</b> </p> <p>Vascular dementia is a common form of dementia caused by poor blood flow to the brain. There are currently no proven and licenced treatments for vascular dementia. Cerebrolysin is a medicine that is made from pig's brains and given as an injection. In some countries, Cerebrolysin is used as a treatment for vascular dementia. A previous summary from 2013 considered all studies of Cerebrolysin and vascular dementia. A definitive conclusion as to whether Cerebrolysin was beneficial could not be made. </p> <p><b>Purpose of this review</b> </p> <p>We wanted to learn whether Cerebrolysin can benefit people living with vascular dementia. We were particularly interested in the effects of the medication on memory and thinking; daily functioning; side effects; and and quality of life for people with vascular dementia and their caregivers. As some time has passed since the last review of Cerebrolysin, we wanted to update the review with a search for any new studies. </p> <p><b>What we did</b> </p> <p>We searched for studies that described the effect of Cerebrolysin in people living with vascular dementia. We searched databases of scientific studies, including resources from countries where Cerebrolysin is commonly used. To be included in our review, the studies had to randomly decide whether people were treated with Cerebrolysin or a comparison. We combined the results of the included studies to estimate the effect of Cerebrolysin. We also assessed how well the studies were conducted and how credible the results were. The evidence is current to May 2019. </p> <p><b>What we found</b> </p> <p>We found six studies including a total of 597 people living with vascular dementia. The method of Cerebrolysin treatment differed across studies, with varying strengths of Cerebrolysin and treatment durations. The studies reported that Cerebrolysin had beneficial effects on memory and thinking and on daily functioning. There was no reported risk of side effects with treatment. None of the studies described quality of life of people living with vascular dementia or their caregivers. </p> <p>Although the studies suggested a benefit of Cerebrolysin treatment, the results are not definitive. The included studies had several issues that may have led to misleading results. Even if the benefit reported in the studies is real, the effect was modest and may not be important to people living with dementia. There is a need for a large, well‐conducted study to better understand if Cerebrolysin is a useful treatment for people living with vascular dementia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008900-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008900-sec-0088"></div> <h3 class="title" id="CD008900-sec-0089">Implications for practice</h3> <section id="CD008900-sec-0089"> <p>The results of our review are encouraging, but we suspect that the strength of evidence will be insufficient to change practice in those countries where Cerebrolysin is not routinely used. Equally, whilst we have voiced some concerns about the quality of the evidence, our results are probably not sufficient to change practice in those centres that are already convinced about the clinical benefits of Cerebrolysin. </p> <p>Although the available evidence suggests that Cerebrolysin is not associated with serious adverse events, there is a substantial burden and cost for a treatment that is given by frequent intravenous infusion. Information was insufficient to make informed decisions about the economics of this therapy. At the population level, we have no effective treatments for vascular dementia, and any treatment that reduces cognitive decline may have important effects. However, at the level of the individual patient, treatment effects may be modest at best and may not seem worthwhile. </p> </section> <h3 class="title" id="CD008900-sec-0090">Implications for research</h3> <section id="CD008900-sec-0090"> <p>There remains equipoise regarding the use of Cerebrolysin in vascular dementia. We found no records of ongoing trials of Cerebrolysin in an exclusive vascular dementia population. Our review demonstrates the need for a new, well‐designed, randomised, placebo‐controlled trial to evaluate the efficacy, safety, and economics of Cerebrolysin in individuals with vascular dementia. </p> <p>Based on this review, we can offer some guidance for a future Cerebrolysin randomised controlled trial. Future studies must: </p> <p> <ol id="CD008900-list-0002"> <li> <p>follow the CONSORT statement for reporting of randomised controlled trials (<a href="./references#CD008900-bbs2-0112" title="SchulzKF , AltmanDG , MoherD , CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. British medical journal2010;340:698‐702. ">Schulz 2010</a>); </p> </li> <li> <p>follow a prespecified design as described in a protocol that is publicly accessible;</p> </li> <li> <p>employ a study design with sufficiently large sample size and long‐term follow‐up so that meaningful changes in cognitive scores can be assessed; </p> </li> <li> <p>include outcomes that are important to people living with dementia;</p> </li> <li> <p>have data to permit a health economic analysis.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008900-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008900-sec-0022"></div> <div class="table" id="CD008900-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Cerebrolysin for vascular dementia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cerebrolysin for vascular dementia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> vascular dementia<br/> <b>Setting:</b> hospitals and clinics<br/> <b>Intervention:</b> Cerebrolysin<br/> <b>Comparison:</b> placebo or routine treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo<br/> (mean)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement<br/> in change score<br/> between<br/> Cerebrolysin and<br/> placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95%<br/> CI) meta‐analysis<br/> findings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function</p> <p>(MMSE or ADAS‐cog+)<br/> follow‐up: 4 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean MMSE<br/> score at baseline<br/> was 19.9.<br/> Mean change from baseline of MMSE was 2.6. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.1 higher<br/> (0.37 higher to 1.82 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36 (0.13 to 0.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as</p> <p>standardised mean difference</p> <p>(<a href="./references#CD008900-fig-0012" title="">Analysis 1.1</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data on quality of life during the treatment and follow‐up periods were available from any of the included trials. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caregiver burden</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data on evaluation of caregiver burden were available from the included trials.</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Binary outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or routine treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Cerebrolysin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in cognitive function reported as responder rates</p> <p>(MMSE, ADAS‐cog+, and HDS)<br/> follow‐up: 15 days to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>554 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>809 per 1000<br/> (610 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.46<br/> (1.10 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR and control group risk from 3 studies (<a href="./references#CD008900-fig-0015" title="">Analysis 1.4</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in global function reported as response rates</p> <p>(CIBIC+ and CGI)<br/> follow‐up: 4 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>388 per 1000<br/> (263 to 575) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.69<br/> (1.82 to 3.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>379<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR and control group risk from 2 studies (<a href="./references#CD008900-fig-0017" title="">Analysis 2.1</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events<br/> follow‐up: 4 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (23 to 229) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/> (0.29 to 2.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>379<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR and control group risk from 2 studies (<a href="./references#CD008900-fig-0020" title="">Analysis 3.2</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>ADAS‐cog+:</b> Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version; <b>CGI:</b> Clinical Global Impression; <b>CI:</b> confidence interval; <b>CIBIC+:</b> Clinician's Interview‐Based Impression of Change plus Caregiver Input; <b>HDS:</b> Hasegawa Dementia Scale; <b>MD:</b> mean difference; <b>MMSE:</b> Mini‐Mental State Examination; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to serious concern about indirectness: the dementia care provided as comparator was not always consistent with contemporary, guideline‐based best care and so there were issues with indirectness.<br/> <sup>2</sup>Downgraded two levels due to very serious concern about risk of bias: two of the trials were at unclear risk of selection bias and unclear risk of reporting bias, and one trial was at unclear risk of detection bias. Most of the 'Risk of bias' judgements were unclear risk of bias.<br/> <sup>3</sup>Downgraded one level due to serious concern about imprecision: modest sample size.<br/> <sup>4</sup>Downgraded two levels due to very serious concern about risk of bias: two of the trials were at unclear risk of selection bias; one trial was at unclear risk of reporting bias; one trial was at unclear of other bias; one trial was at high risk of performance bias, high risk of detection bias, and high risk of reporting bias. There was a substantial risk of bias across the body of evidence.<br/> <sup>5</sup>Downgraded one level due to serious concern about imprecision: modest sample size and few events.<br/> <sup>6</sup>Downgraded two levels due to very serious concern about risk of bias: one of the trials was at unclear risk of selection bias, unclear risk of detection bias, and unclear risk of reporting bias. Most of the 'Risk of bias' judgements were unclear risk of bias.<br/> <sup>7</sup>Downgraded one level due to serious concern about imprecision: modest sample size and wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008900-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008900-sec-0023"></div> <section id="CD008900-sec-0024"> <h3 class="title" id="CD008900-sec-0024">Description of the condition</h3> <section id="CD008900-sec-0025"> <h4 class="title">Definition</h4> <p>Vascular dementia (VaD) is the second most common form of dementia after Alzheimer's disease (AD). The term 'vascular dementia' refers to a constellation of cognitive and functional impairments all caused by disordered blood flow to the brain. Vascular dementia can be considered a subset of the larger syndrome of vascular cognitive impairment (VCI), that is all cognitive syndromes associated with a cerebrovascular brain injury (<a href="./references#CD008900-bbs2-0039" title="AggarwalNT , DecarliC . Vascular dementia: emerging trends. Seminars in Neurology2007;27(1):66‐77. ">Aggarwal 2007</a>). As an aetiologic category, VaD includes dementia caused by ischaemic or haemorrhagic cerebrovascular diseases (CVD) or by ischaemic‐hypoxic brain lesions of cardiovascular origin (<a href="./references#CD008900-bbs2-0109" title="RománGC . Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Medical Clinics of North America2002;86(3):477‐99. ">Román 2002</a>). </p> </section> <section id="CD008900-sec-0026"> <h4 class="title">Diagnosis and classification</h4> <p>There are several diagnostic criteria for VaD, such as the Diagnostic and Statistical Manual of Mental Disorders, third edition, third revised, fourth, and fifth edition (DSM‐III, DSM III‐R, DSM‐IV, DSM‐V) (<a href="./references#CD008900-bbs2-0043" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Press, 1980. ">APA 1980</a>; <a href="./references#CD008900-bbs2-0044" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition, revised. Washington, DC: American Psychiatric Press, 1987. ">APA 1987</a>; <a href="./references#CD008900-bbs2-0045" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Press, 1994. ">APA 1994</a>; <a href="./references#CD008900-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Association, 2013. ">APA 2013</a>), Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC) criteria (<a href="./references#CD008900-bbs2-0056" title="ChuiHC , VictoroffJI , MargolinD . Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer's disease diagnostic and treatment centers. Neurology1992;42:473‐80. ">Chui 1992</a>), International Statistical Classification of Diseases, 10th revision (ICD‐10) (<a href="./references#CD008900-bbs2-0124" title="World Health Organization. The 10th Revision of the International Classification of Disease and Related Health Problems (ICD‐10). Geneva: World Health Organization, 1992. ">WHO 1992</a>), and National Institute of Neurological Disorders and Stroke ‐ Association Internationale Pour la Recherche et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria (<a href="./references#CD008900-bbs2-0108" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology1993;43:250‐60. ">Román 1993</a>). All of these criteria are based on two major requirements: clinical diagnosis of dementia and determination of its vascular origin. The latter requirement is problematic because of the frequent overlap between cerebrovascular and degenerative disorders, particularly in older people (<a href="./references#CD008900-bbs2-0048" title="BenistyS , HernandezK , ViswanathanA . Diagnostic criteria of vascular dementia in CADASIL. Stroke2008;39:838‐44. ">Benisty 2008</a>). As a result, the current diagnostic criteria for VaD are not concordant, which could make data analysis and comparisons difficult (<a href="./references#CD008900-bbs2-0090" title="MoorhouseP , RockwoodK . Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology2008;7:246‐55. ">Moorhouse 2008</a>). </p> <p>Within the VaD rubric, the following has been proposed as a classification of the subtypes of VaD (<a href="./references#CD008900-bbs2-0096" title="O'BrienJT , ThomasA . Vascular dementia. Lancet2015;386(10004):1698‐706. [PUBMED: 26595643] ">O'Brien 2015</a>): </p> <p>(i) multi‐infarct dementia (cortical VaD);</p> <p>(ii) small‐vessel dementia (subcortical VaD);</p> <p>(iii) strategic infarct dementia;</p> <p>(iv) hypoperfusion dementia;</p> <p>(v) haemorrhagic dementia;</p> <p>(vi) AD with cerebrovascular disease (CVD);</p> <p>(vii) hereditary vascular dementia (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)). </p> <p>This classification is based on clinical differences and underlying pathologic changes. Although each category is well defined, in many cases it can be difficult to classify a patient into one definitive subtype. Subtypes are usually not pure. Rather, mixtures of pathologies frequently combine to contribute to cognitive impairment (<a href="./references#CD008900-bbs2-0090" title="MoorhouseP , RockwoodK . Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology2008;7:246‐55. ">Moorhouse 2008</a>). </p> <p>Vascular dementia and stroke disease are closely linked, but the terms VaD and poststroke dementia (PSD) are not synonymous (<a href="./references#CD008900-bbs2-0087" title="MijajlovićMD , PavlovićA , BraininM , HeissWD , QuinnTJ , Ihle‐HansenHB , et al. Post‐stroke dementia ‐ a comprehensive review. BMC medicine 2017 Jan 18;15(1):11. ">Mijajlović 2017</a>). Although most PSD cases are pathologically confirmed as VaD, some have been reported to be other dementia‐related pathologies, such as AD (<a href="./references#CD008900-bbs2-0077" title="IharaM , KalariaRN . Understanding and preventing the development of post‐stroke dementia. Expert review of neurotherapeutics2014;14(9):1067‐77. ">Ihara 2014</a>). </p> </section> <section id="CD008900-sec-0027"> <h4 class="title">Assessment</h4> <p>A wide range of instruments have been used to assess cognitive function in individuals with VaD (<a href="./references#CD008900-bbs2-0082" title="KorczynAD , VakhapovaV , GrinbergLT . Vascular dementia. Journal of the Neurological Sciences2012;322(1‐2):2‐10. ">Korczyn 2012</a>). However, since the most typical expression of VaD is executive dysfunction, the widely used Mini‐Mental State Examination (MMSE) may underestimate the cognitive decline in individuals with VaD. Mini‐Mental State Examination was designed to assess for Alzheimer’s disease and contains few items related to executive function (<a href="./references#CD008900-bbs2-0061" title='FolsteinMF , FolsteinSE , McHughPR . "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. '>Folstein 1975</a>; <a href="./references#CD008900-bbs2-0090" title="MoorhouseP , RockwoodK . Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology2008;7:246‐55. ">Moorhouse 2008</a>). Other cognitive assessment tools such as the Montreal Cognitive Assessment (MoCA) may be more appropriate in such cases (<a href="./references#CD008900-bbs2-0093" title="NasreddineZS ,  PhillipsNA ,  BédirianV ,  CharbonneauS ,  WhiteheadV ,  CollinI ,  etal . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatric Society2005;53(4):695‐9. ">Nasreddine 2005</a>; <a href="./references#CD008900-bbs2-0082" title="KorczynAD , VakhapovaV , GrinbergLT . Vascular dementia. Journal of the Neurological Sciences2012;322(1‐2):2‐10. ">Korczyn 2012</a>). </p> </section> <section id="CD008900-sec-0028"> <h4 class="title">Global burden of disease</h4> <p>Vascular dementia has traditionally received less attention than AD, yet international epidemiological data suggest a substantial global burden from VaD. The prevalence rate of VaD has been estimated to double every 5.3 years, compared with every 4.5 years for AD (<a href="./references#CD008900-bbs2-0094" title="O'BrienJT , ErkinjunttiT , ReisbergB . Vascular cognitive impairment. Lancet Neurology2003;2(2):89–98. ">O'Brien 2003</a>). In North America, AD accounts for 44% to 70% of all dementia, while VaD accounts for 14.5% to 20% (<a href="./references#CD008900-bbs2-0100" title="PlassmanBL , LangaKM , FisherGG , HeeringaSG , WeirDR , OfstedalMB , et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology2007;29(1‐2):125‐32. ">Plassman 2007</a>; <a href="./references#CD008900-bbs2-0064" title="GoodmanRA , LochnerKA , ThambisettyM , WingoTS , PosnerSF , LingSM . Prevalence of dementia subtypes in United States Medicare fee‐for‐service beneficiaries, 2011‐2013. Alzheimer's &amp; dementia2017;13(1):28‐37. ">Goodman 2017</a>). Studies in the UK have estimated the incidence rate of AD as 1.59/1000 person‐years, whilst the incidence rate of VaD was 0.99 cases/1000 person‐years (<a href="./references#CD008900-bbs2-0078" title="ImfeldP , Brauchli PernusYB , JickSS , MeierCR . Epidemiology, co‐morbidities, and medication use of patients with Alzheimer's disease or vascular dementia in the UK. Journal of Alzheimer's disease2013;35(3):565‐73. ">Imfeld 2013</a>). The prevalence of VaD among individuals aged 65 years and older was 1.50% in China between 2008 and 2009, while AD was the leading cause of dementia (3.21%) (<a href="./references#CD008900-bbs2-0080" title="JiaJ , WangF , WeiC , ZhouA , JiaX , LiF , et al. The prevalence of dementia in urban and rural areas of China. Alzheimer's &amp; dementia2014;10(1):1‐9. ">Jia 2014</a>). Although earlier studies in Japanese populations demonstrated a greater prevalence of VaD than AD, recent studies have shown that the trend has shifted with no changes in VaD prevalence and increases in AD prevalence over time (<a href="./references#CD008900-bbs2-0097" title="OharaT , HataJ , YoshidaD , MukaiN , NagataM , IwakiT , et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology2017;88(20):1925‐32. ">Ohara 2017</a>). </p> </section> <section id="CD008900-sec-0029"> <h4 class="title">Treatment</h4> <p>Despite its prevalence and societal impact, there is no definitive, proven pharmacological treatment for VaD. Potential interventions may be considered at a number of levels: primary prevention, secondary prevention, symptomatic treatments, and disease‐modifying or curative approaches (<a href="./references#CD008900-bbs2-0095" title="O'BrienJT . Vascular cognitive impairment. American Journal of Geriatric Psychiatry2006;14:724‐33. ">O'Brien 2006</a>). The currently available data on the treatment of vascular risk factors does not prove a benefit in primary and secondary prevention (<a href="./references#CD008900-bbs2-0090" title="MoorhouseP , RockwoodK . Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology2008;7:246‐55. ">Moorhouse 2008</a>). Trials of monotherapies such as antiplatelet agent or statins for the prevention or treatment of VaD are also equivocal (<a href="./references#CD008900-bbs2-0086" title="McGuinnessB , CraigD , BullockR , MaloufR , PassmoreP . Statins for the treatment of dementia. Cochrane Database of Systematic Reviews2014, Issue 7. ">McGuinness 2014</a>; <a href="./references#CD008900-bbs2-0096" title="O'BrienJT , ThomasA . Vascular dementia. Lancet2015;386(10004):1698‐706. [PUBMED: 26595643] ">O'Brien 2015</a>; <a href="./references#CD008900-bbs2-0055" title="ChuCS , TsengPT , StubbsB , ChenTY , TangCH , LiDJ , et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta‐analysis. Scientific reports2018;8(1):1‐12. ">Chu 2018</a>). Recent meta‐analysis of longitudinal trials and randomised clinical trials have shown, albeit far from conclusively, that hypertension is a potential risk factor for VaD and that antihypertensive medication use may decrease the risk of VaD (<a href="./references#CD008900-bbs2-0114" title="ShahK , QureshiSU , JohnsonM , ParikhN , SchulzPE , KunikME . Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. American journal of geriatric pharmacotherapy2009;7(5):250‐61. ">Shah 2009</a>; <a href="./references#CD008900-bbs2-0084" title="LigthartSA , Moll van CharanteEP , VanGoolWA , RichardE . Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vascular health and risk management2010, (6):775‐85. ">Ligthart 2010</a>; <a href="./references#CD008900-bbs2-0052" title="ChangQH , HuiW , ChaoMW , ZhengRW , JunWG , YongHL , et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta‐analysis of longitudinal studies. International Journal of Clinical Practice2011;65(12):1295‐305. ">Chang 2011</a>; <a href="./references#CD008900-bbs2-0115" title="SharpSI , AarslandD , DayS , SønnesynH , Alzheimer's Society Vascular Dementia Systematic Review Group, BallardC . Hypertension is a potential risk factor for vascular dementia: systematic review. International journal of geriatric psychiatry2011;26(7):661‐9. ">Sharp 2011</a>). Although the effects of cardiovascular drugs on VaD per se are unproven, these vascular primary and secondary prevention strategies have proven efficacy in preventing stroke, which will in turn contribute to vascular cognitive decline. </p> <p>Potential symptomatic treatment for VaD, such as vasodilators, nootropics, antioxidants (<a href="./references#CD008900-bbs2-0095" title="O'BrienJT . Vascular cognitive impairment. American Journal of Geriatric Psychiatry2006;14:724‐33. ">O'Brien 2006</a>; <a href="./references#CD008900-bbs2-0090" title="MoorhouseP , RockwoodK . Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology2008;7:246‐55. ">Moorhouse 2008</a>; <a href="./references#CD008900-bbs2-0099" title="PerezL , HeimL , SherzaiA , Jaceldo‐SieglK , SherzaiA . Nutrition and vascular dementia. journal of nutrition, health &amp; aging2012;16(4):319‐24. ">Perez 2012</a>), and some traditional Chinese herbal medicines (<a href="./references#CD008900-bbs2-0126" title="WuTX , LiQP , YuanZY . Yizhi capsule for vascular dementia. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005382.pub2] ">Wu 2007</a>; <a href="./references#CD008900-bbs2-0067" title="HaoZ , LiuM , LiuZ . Huperzine A for vascular dementia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007365.pub2] ">Hao 2009</a>; <a href="./references#CD008900-bbs2-0128" title="XuQQ , ShanCS , WangY , ShiYH , ZhangQH , ZhengGQ . Chinese herbal medicine for vascular dementia: a systematic review and meta‐analysis of high‐quality randomized controlled trials. Journal of Alzheimer's disease2018;62(1):429‐56. ">Xu 2018</a>), have been evaluated in multiple trials and systematic reviews with disappointing results. The effects of drugs used to treat AD are modest when used in people living with VaD (<a href="./references#CD008900-bbs2-0090" title="MoorhouseP , RockwoodK . Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurology2008;7:246‐55. ">Moorhouse 2008</a>): rivastigmine and galatimine provide only modest benefit of uncertain clinical significance and higher rate of side effects (<a href="./references#CD008900-bbs2-0058" title="CraigD , BirksJ . Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews2006, Issue 1. ">Craig 2006</a>; <a href="./references#CD008900-bbs2-0049" title="BirksJ , McGuinnessB , CraigD . Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews2013, Issue 5. ">Birks 2013</a>). </p> </section> </section> <section id="CD008900-sec-0030"> <h3 class="title" id="CD008900-sec-0030">Description of the intervention</h3> <p>Cerebrolysin is a neuropeptide preparation produced by standardised enzymatic breakdown of porcine brain proteins. It is a mixture of 80% low‐molecular‐weight peptides and 20% free amino acids. Cerebrolysin is said to have potential neurotrophic and neuroprotective properties (<a href="./references#CD008900-bbs2-0125" title="WindischM , GschanesA , Hutter‐PaierB . Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. Journal of Neural Transmission Supplement1998;53:289‐98. ">Windisch 1998</a>; <a href="./references#CD008900-bbs2-0134" title="ÁlvarezXA , CacabelosR , LaredoM . A 24‐week, double‐blind, placebo‐controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. European Journal of Neurology2006;13(1):43‐54. ">Álvarez 2006</a>; <a href="./references#CD008900-bbs2-0136" title="ÁlvarezXA , FuentesP . Cerebrolysin in Alzheimer's disease. Drugs Today (Barc)2011;47(7):487‐513. ">Álvarez 2011b</a>). </p> <p>Cerebrolysin is currently used for the treatment of dementia in a number of European and Asian countries. As a potential treatment for dementia, Cerebrolysin is supplied as a solution for injection or infusion, and it is recommended to be given as intravenous infusion once daily. Treatment is usually given in cycles; a typical cycle would be treatment five days a week repeated for four weeks, with two to four treatment cycles per year ( <a href="./references#CD008900-bbs2-0101" title="PloskerGL ,  GauthierS . Cerebrolysin: a review of its use in dementia. Drugs and Aging2009;26(11):893‐915. ">Plosker 2009</a>). </p> <p>Cerebrolysin has also been reported as having beneficial effects on cognitive and physical function in various other neurological conditions, including stroke (<a href="./references#CD008900-bbs2-0075" title="HongZ , ZhuGX , ChenHB , ChenSD , YangQD , ZengJS , et al. The clinical efficacy of Cerebrolysin in the treatment of acute ischemic stroke [施普善在缺血性脑卒中急性期的临床疗效研究]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases2005;7:331‐3. ">Hong 2005</a>; <a href="./references#CD008900-bbs2-0083" title="LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415‐28. ">Ladurner 2005</a>; <a href="./references#CD008900-bbs2-0063" title="GharagozliK , HarandiAA , HoushmandS , AkbariN , MuresanuDF , VesterJ , et al. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo‐controlled, double‐blinded, multicenter clinical trial. Journal of medicine and life2017;10(3):153‐60. ">Gharagozli 2017</a>), AD (<a href="./references#CD008900-bbs2-0134" title="ÁlvarezXA , CacabelosR , LaredoM . A 24‐week, double‐blind, placebo‐controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. European Journal of Neurology2006;13(1):43‐54. ">Álvarez 2006</a>; <a href="./references#CD008900-bbs2-0062" title="GauthierS , ProañoJV , JiaJ , FroelichL , VesterJC , DopplerE . Cerebrolysin in mild‐to‐moderate Alzheimer's disease: a meta‐analysis of randomized controlled clinical trials. Dementia and geriatric cognitive disorders2015;39(5‐6):332‐47. ">Gauthier 2015</a>), and traumatic brain injury (<a href="./references#CD008900-bbs2-0133" title="ÁlvarezXA , SampedroC , PérezP , LaredoM , CouceiroV , HernándezÁ , et al. Positive effects of Cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. International Clinical Psychopharmacology2003;18(5):271‐8. ">Álvarez 2003</a>; <a href="./references#CD008900-bbs2-0053" title="ChenCC , WeiST , TsaiaSC , ChenXX , ChoDY . Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double‐blind, placebo‐controlled, randomized study. British journal of neurosurgery2013;27(6):803‐7. ">Chen 2013a</a>). </p> </section> <section id="CD008900-sec-0031"> <h3 class="title" id="CD008900-sec-0031">How the intervention might work</h3> <p>Various in vitro and in vivo studies have shown that Cerebrolysin has pharmacodynamic properties similar to those of endogenous neurotrophic factors. For example, it exerts nerve growth factor (NGF)‐like activity on neurons and increases levels of NGF (<a href="./references#CD008900-bbs2-0120" title="UbhiK , RockensteinE , Vazquez‐RoqueR , ManteM , InglisC , PatrickC , et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. Journal of neuroscience research2013;91(2):167‐77. ">Ubhi 2013</a>). Various animal models have been established to demonstrate the neurotrophic and pro‐cognitive effects of Cerebrolysin (<a href="./references#CD008900-bbs2-0121" title="VeinbergsI , ManteM , MalloryM . Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. Journal of Neural Transmission Supplement2000;59:273‐80. ">Veinbergs 2000</a>; <a href="./references#CD008900-bbs2-0105" title="RockensteinE , AdameA , ManteM . Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. Journal of Neural Transmission2005;112(2):269‐82. ">Rockenstein 2005</a>; <a href="./references#CD008900-bbs2-0120" title="UbhiK , RockensteinE , Vazquez‐RoqueR , ManteM , InglisC , PatrickC , et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. Journal of neuroscience research2013;91(2):167‐77. ">Ubhi 2013</a>). </p> <p>Pleiotropic properties include promotion of neuroprotection, neuroplasticity, and neurogenesis. Suggested underlying mechanisms for these actions include the following. </p> <p>(1) Reduced amyloid plaque formation by regulating amyloid precursor protein (APP) (<a href="./references#CD008900-bbs2-0106" title="RockensteinE , TorranceM , ManteM , AdameA , PaulinoA , RoseJB , et al. Cerebrolysin decreases amyloid‐beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Journal of Neuroscience Research2006;83:1252‐61. ">Rockenstein 2006</a>; <a href="./references#CD008900-bbs2-0131" title="ZhangY , ChoppM , MengY , ZhangZG , DopplerE , WinterS , et al. Cerebrolysin improves cognitive performance in rats after mild traumatic brain injury. Journal of neurosurgery2015;122(4):843‐55. ">Zhang 2015</a>). </p> <p>(2) Inhibition of calpain, caspase‐3, Bcl‐2 and upregulation of Bax, thus protecting neurons from apoptosis and degeneration (<a href="./references#CD008900-bbs2-0040" title="AkaiF , HirumaS . Neurotrophic factor‐like effect of FPF1070 on septal cholinergic neurons after transections of fimbria‐fornix in the rat brain. Histology and Histopathology1992;7(2):213‐21. ">Akai 1992</a>; <a href="./references#CD008900-bbs2-0068" title="HartbauerM , Hutter‐PaierB , WindischM . Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. Journal of Neural Transmission2001;108:581‐92. ">Hartbauer 2001</a>; <a href="./references#CD008900-bbs2-0127" title="XingS , ZhangJ , DangC , LiuG , ZhangY , LiJ , et al. Cerebrolysin reduces amyloid‐β deposits, apoptosis and autophagy in the thalamus and improves functional recovery after cortical infarction. Journal of the Neurological Sciences2014;337(1‐2):104‐11. ">Xing 2014</a>). </p> <p>(3) Induction of modifications in dendritic morphology by increasing the dendritic length, density, and spine density, ameliorating dendritic pathology and spine loss, whilst increasing the levels of plasticity‐related synaptic proteins, thereby improving structural synaptic plasticity (<a href="./references#CD008900-bbs2-0081" title="JuárezI , GonzálezDJ , MenaR , FloresG . The chronic administration of cerebrolysin induces plastic changes in the prefrontal cortex and dentate gyrus in aged mice. Synapse2011;65(11):1128‐35. ">Juárez 2011</a>; <a href="./references#CD008900-bbs2-0041" title="Alcántara‐GonzálezF , Mendoza‐PerezCR , ZaragozaN , JuarezI , Arroyo‐GarcíaLE , GamboaC , et al. Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice. Synapse2012;66(11):938‐49. ">Alcántara‐González 2012</a>; <a href="./references#CD008900-bbs2-0122" title="Vázquez‐RoqueRA , UbhiK , MasliahE , FloresG . Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat. Synapse2014;68(1):31‐8. ">Vázquez‐Roque 2014</a>; <a href="./references#CD008900-bbs2-0085" title="LiuZ , HuM , LuP , WangH , QiQ , XuJ , et al. Cerebrolysin alleviates cognitive deficits induced by chronic cerebral hypoperfusion by increasing the levels of plasticity‐related proteins and decreasing the levels of apoptosis‐related proteins in the rat hippocampus. Neuroscience letters2017;651:72‐8. ">Liu 2017b</a>). </p> <p>(4) Attenuating the physiological apoptosis of neuroblasts, augmenting the survival of neural progenitor cells, and enhancing neural progenitor cell proliferation and neuronal differentiation, thus stimulating neurogenesis (<a href="./references#CD008900-bbs2-0119" title="TatebayashiY , LeeMH , LiL , IqbalK , Grundke‐lqbalI . The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathologica2003;105(3):225‐32. ">Tatebayashi 2003</a>; <a href="./references#CD008900-bbs2-0107" title="RockensteinE , ManteM , AdameA , CrewsL , MoesslerH , MasliahE . Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease. Acta neuropathologica2007;113(3):265‐75. ">Rockenstein 2007</a>; <a href="./references#CD008900-bbs2-0129" title="ZhangC , ChoppM , CuiY , WangL , ZhangR , ZhangL , et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of neuroscience research2010;88(15):3275‐81. ">Zhang 2010</a>; <a href="./references#CD008900-bbs2-0050" title="BornsteinN , PoonWS . Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries. Drugs of Today2012;48 Suppl A:43‐61. ">Bornstein 2012</a>; <a href="./references#CD008900-bbs2-0130" title="ZhangL , ChoppM , MeierDH , WinterS , WangL , SzaladA , et al. Sonic hedgehog signaling pathway mediates cerebrolysin‐improved neurological function after stroke. Stroke2013;44(7):1965‐72. ">Zhang 2013</a>). </p> </section> <section id="CD008900-sec-0032"> <h3 class="title" id="CD008900-sec-0032">Why it is important to do this review</h3> <p>Cerebrolysin is widely used for the treatment of stroke, traumatic brain injuries, and dementia in Russia, Eastern European countries, China, and other Asian countries. Given the lack of treatments and global prevalence of VaD, if beneficial effects of Cerebrolysin are proven then this will have major implications for global healthcare policy and practice. </p> <p>Systematic reviews of Cerebrolysin used in other neurological conditions have not reported convincing efficacy. These reviews have also highlighted concerns over adverse effects and the methodological quality of included studies. For example, the Cochrane Review of Cerebrolysin in acute ischaemic stroke reported no clinical benefits and found increased risk of serious adverse events (<a href="./references#CD008900-bbs2-0132" title="ZiganshinaLE , AbakumovaT . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 6. ">Ziganshina 2015</a>). Another systematic review suggests that Cerebrolysin may have benefits in in traumatic brain injury, but the validity of the conclusion was weakened by imprecision and methodological flaws of the included studies (<a href="./references#CD008900-bbs2-0060" title="ElSayedI , ZakiA , FayedAM , ShehataGM , AbdelmonemS . A meta‐analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurgical Review2018;41(2):427‐38. ">El Sayed 2018</a>). The previous Cochrane Review of Cerebrolysin in VaD(<a href="./references#CD008900-bbs2-0054" title="ChenN , YangM , GuoJ , ZhouM , ZhuC , HeL . Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews2013, Issue 1. ">Chen 2013b</a>) did not find sufficient evidence to support Cerebrolysin treatment, citing low numbers of trials, heterogeneity between trials, and risk of bias. </p> <p>As clinical and research interest in VaD is increasing (<a href="./references#CD008900-bbs2-0051" title="BurnsA , RobertP , IDEAL steering group. Dementia care: international perspectives. Current Opinion in Psychiatry2019;32(4):361‐5. ">Burns 2019</a>), it seemed an appropriate time to update a review of the literature on Cerebrolysin and VaD. There were other motivating factors for updating the review. Since the last review, methods for assessing quality of evidence, particularly the use of GRADE methods, have evolved, and an updated review would permit a synthesis that uses these approaches. As Cerebrolysin is mostly used in Eastern countries, an updated review that included Chinese language databases may also yield additional information. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008900-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008900-sec-0033"></div> <p>Primary: to assess the effect of Cerebrolysin on cognitive function, global function, and all‐cause mortality in people living with vascular dementia. </p> <p>Secondary: to assess the adverse effects of Cerebrolysin and to assess the effect of Cerebrolysin on quality of life and caregiver burden. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008900-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008900-sec-0034"></div> <section id="CD008900-sec-0035"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008900-sec-0036"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials (RCTs), without any language restrictions. </p> <p>We included the following potential study designs.<br/> (1) Cerebrolysin alone compared with placebo.<br/> (2) Cerebrolysin alone compared with no treatment.<br/> (3) Cerebrolysin plus another treatment compared with placebo plus the same other treatment.<br/> (4) Cerebrolysin plus another treatment compared with the same other treatment alone. </p> <p>We thus excluded studies where Cerebrolysin was used in both groups as a routine treatment and studies where another treatment was used in only one trial arm. </p> <p>We excluded non<b>‐</b>RCT study designs, for example non‐randomised concurrent control trials, before‐after studies, and cohort studies. </p> </section> <section id="CD008900-sec-0037"> <h4 class="title">Types of participants</h4> <p>We included participants of all ages and both sexes with a diagnosis of vascular dementia. To be included, diagnosis should have been made using accepted, validated criteria, such as the DSM, <a href="./references#CD008900-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Association, 2013. ">APA 2013</a>, or VaD‐specific criteria such as those proposed by the NINDS‐AIREN (<a href="./references#CD008900-bbs2-0108" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology1993;43:250‐60. ">Román 1993</a>). </p> <p>We included studies involving a broader population of dementia or vascular disease if the data for relevant participants with VaD could be extracted. </p> <p>We excluded studies of stroke unless the stroke group, or a subgroup, also had a confirmed diagnosis of VaD. </p> </section> <section id="CD008900-sec-0038"> <h4 class="title">Types of interventions</h4> <p>We included Cerebrolysin given at any dose and for any duration (length of cycle and number of cycles). </p> </section> <section id="CD008900-sec-0039"> <h4 class="title">Types of outcome measures</h4> <p>We included data from validated, cognitive, and functional assessment scales if possible. In cases where the outcome was evaluated by a less established measure, we searched the paper bibliography and reference texts to identify source information about the properties of the test or scale in question.  We used this information to make a group decision as to whether or not to accept the measure as valid. </p> <section id="CD008900-sec-0040"> <h5 class="title">Primary outcomes</h5> <p>(1) Cognitive function (measured by multidomain tools such as MMSE).</p> <p>(2) Global function (measured by tools such as Clinician Interview Based Impression of Change (CIBIC)). </p> <p>(3) All‐cause death.</p> </section> <section id="CD008900-sec-0041"> <h5 class="title">Secondary outcomes</h5> <p>(1) Adverse events.</p> <p>(2) Quality of life (measured by tools such as Dementia Quality of Life Questionnaire (DEMQOL)). </p> <p>(3) Caregiver burden (measured by tools such as the Zarit Burden Interview (ZBI)).</p> </section> </section> </section> <section id="CD008900-sec-0042"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008900-sec-0043"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>), the Cochrane Dementia and Cognitive Improvement Group's Specialized Register, on 9 May 2019. </p> <p>The search terms used were: Cerebrolysin, Cere, FPF1070, FPF‐1070.</p> <p>ALOIS is maintained by the Information Specialists for the Cochrane Dementia and Cognitive Improvement Group and contains studies in the areas of dementia prevention, dementia treatment, and cognitive enhancement in healthy individuals. The studies are identified from:   </p> <p> <ol id="CD008900-list-0001"> <li> <p>monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature), PsycINFO, and LILACS (Latin American and Caribbean Health Science Information database); </p> </li> <li> <p>monthly searches of a number of trial registers: ISRCTN, UMIN (Japan's Trial Register), the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (which covers US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov, ISRCTN, the Chinese Clinical Trials Register, the German Clinical Trials Register, the Iranian Registry of Clinical Trials, and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings, Index to Theses, Australasian Digital Theses. </p> </li> </ol> </p> <p>To view a list of all sources searched for ALOIS, see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL, and conference proceedings can be viewed in the 'methods used in reviews' section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>In order to ensure that the search for the review was as up‐to‐date and comprehensive as possible, we conducted an additional search including: MEDLINE, Embase, PsycINFO, CINAHL, ISI Web of Knowledge, LILACS, CENTRAL, ClinicalTrials.gov, and the WHO ICTRP. The search strategies used are shown in <a href="./appendices#CD008900-sec-0094">Appendix 1</a>. </p> <p>In this updated review, we expanded the search by adding a search of the four most comprehensive and authoritative Chinese databases from 1 January 2012 to 19 May 2019: China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Data Knowledge Service Platform, and China Biology Medicine disc. The review authors translated the original search terms into Chinese. </p> </section> <section id="CD008900-sec-0044"> <h4 class="title">Searching other resources</h4> <p>We checked the references of all relevant studies to identify additional trials. We also contacted the authors of published trials and known experts in the field to identify any additional published or unpublished data. We approached the medical information department of the relevant companies (EVER Neuro Pharma GmbH; Hebei Zhitong Pharmaceutical Group Co. Ltd) with a request for copies of all materials that described clinical studies with Cerebrolysin. </p> </section> </section> <section id="CD008900-sec-0045"> <h3 class="title" id="CD008900-sec-0045">Data collection and analysis</h3> <section id="CD008900-sec-0046"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SH Cui and N Chen) independently scrutinised the titles and abstracts identified by the search. The two review authors obtained the full text of all studies deemed potentially relevant and independently assessed these against the inclusion criteria. Any disagreements on inclusion were resolved through discussion or by consulting a third review author (L He) to arbitrate as needed. </p> </section> <section id="CD008900-sec-0047"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SH Cui and N Chen) independently extracted data from the trials to populate a data extraction form. We included information on: study name, design, participant characteristics, severity of VaD, duration of treatment, dosing of treatment, number of participants at baseline, number of participant withdrawals, participants analysed in the different treatment groups, inclusion and exclusion criteria, and outcomes. We also assessed for funding source. One review author (SH Cui) entered data into Review Manager 2014 (<a href="./references#CD008900-bbs2-0104" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and a second review author (N Chen) checked the data entry. </p> </section> <section id="CD008900-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (N Chen and M Yang) independently assessed risk of bias of the included trials using the Cochrane 'Risk of bias' tool for the following domains (<a href="./references#CD008900-bbs2-0074" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <p>• Sequence generation (selection bias)</p> <p>• Allocation concealment (selection bias)</p> <p>• Blinding of participants and personnel (performance bias)</p> <p>• Blinding of outcome assessment (detection bias)</p> <p>• Incomplete outcome data (attrition bias)</p> <p>• Selective reporting (reporting bias)</p> <p>• Any other bias</p> <p>Any disagreements were resolved by discussion or by consulting a third assessor (L He). </p> <p>We assigned a summary label of low risk of bias only when all individual domains were assessed as low risk of bias. We assigned a summary label of high risk of bias when any domain was assessed as high risk of bias. An issue with the previous Cerebrolysin review (<a href="./references#CD008900-bbs2-0054" title="ChenN , YangM , GuoJ , ZhouM , ZhuC , HeL . Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews2013, Issue 1. ">Chen 2013b</a>) was that poor reporting in the primary studies forced a label of 'unclear' for many of the 'Risk of bias' domains. In this review, where a domain was considered to be unclear even after we had contacted the study authors, we considered it likely that risk of bias was present, and this informed our GRADE assessment. </p> </section> <section id="CD008900-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the data using Cochrane Review Manager 5 software. We expressed the results as risk ratio (RR) with 95% confidence intervals (95% CI) for dichotomous outcomes, and mean differences (MD) or standardised mean differences (SMD) with 95% CI for continuous outcomes. If a paper only reported an outcome with accompanying standard error, we used the Review Manager 5 generic inverse variance feature to permit inclusion of the data in summary analyses. </p> </section> <section id="CD008900-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <p>We considered only participant‐level outcomes. In order to avoid unit of analysis errors resulting from combining results from more than one time point, we used final time point data from each trial. We planned to analyse subgroups based on treatment duration where possible (<a href="./references#CD008900-bbs2-0059" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). For studies that compared more than two groups, we selected the paired comparison most relevant to the review question or combined intervention groups as appropriate. </p> </section> <section id="CD008900-sec-0051"> <h4 class="title">Dealing with missing data</h4> <p>For all included studies, we extracted and presented numbers of participants lost to follow‐up, with reasons, in <a href="./references#CD008900-sec-0103" title="">Characteristics of included studies</a>. Where these data were not clear in the published paper, we requested the information from the study authors. We analysed data on an intention‐to‐treat (ITT) basis, reporting any imputation methods used in the primary studies (<a href="./references#CD008900-sec-0103" title="">Characteristics of included studies</a>). In the case of missing data for non‐completers, the study authors used 'last observation carried forward' data, which we included in our analyses of treatment outcomes. </p> </section> <section id="CD008900-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity between trials using the Chi<sup>2</sup> test with a 10% level of statistical significance (P &lt; 0.1) and I<sup>2</sup> &gt; 50% (<a href="./references#CD008900-bbs2-0070" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD008900-bbs2-0071" title="HigginsJP , ThompsonSG , DeeksJJ . Measuring inconsistency in meta‐analyses. British medical journal2003;327(7414):557‐60. ">Higgins 2003</a>). If significant heterogeneity was present, we performed a cause analysis, and then undertook subgroup and sensitivity analyses. We also planned to explore possible causes of heterogeneity by conducting meta‐regression analysis where applicable. </p> </section> <section id="CD008900-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use a funnel plot to investigate the possibility of publication bias if necessary, and then to evaluate and express the possible reporting biases. We would only perform tests for funnel plot asymmetry if more than 10 studies were included, which is thought to to give sufficient power to distinguish chance from real asymmetry (<a href="./references#CD008900-bbs2-0118" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> <section id="CD008900-sec-0054"> <h4 class="title">Data synthesis</h4> <p>We used standard Cochrane methods to create forest plots and perform meta‐analysis. We used fixed‐effect models for analyses with homogeneity. When we considered that there was important clinical heterogeneity between studies, or when the quantitative measure of heterogeneity was greater than 50%, we used a random‐effects model. </p> <p>For trials that were too clinically heterogeneous or presented insufficient information for pooling, we performed a descriptive analysis (<a href="./references#CD008900-bbs2-0059" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD008900-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, we carried out subgroup analyses to explore potential sources of heterogeneity.</p> </section> <section id="CD008900-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook a sensitivity analysis on the basis of methodological quality, omitting those trials with unclear or high risk of bias. </p> <section id="CD008900-sec-0057"> <h5 class="title">Presentation of results and 'Summary of findings' tables</h5> <p>Within our cognition outcome, we were able to present data on change in scores from multidomain cognitive assessment tools and on domain‐specific tests. </p> <p>Within our general function outcome, we were able to describe data as percentage change in functional status. </p> <p>We used the five GRADE considerations (study limitations, inconsistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the body of evidence (studies that contribute data for the prespecified outcomes) (<a href="./references#CD008900-bbs2-0110" title="RyanR , HillS . How to GRADE the quality of the evidence. CCCG. Version 3.0. cccrg.cochrane.org/author‐resources. Melbourne: La Trobe University, (accessed prior to 11 September 2019). ">Ryan 2016</a>). We downgraded the evidence from 'high quality' by one level when one of these factors was present to a serious degree, and two levels if very serious. As only RCTs were eligible for inclusion in the review, reasons for upgrading (large effect, dose response, and plausible confounding factors) were not applicable. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008900-bbs2-0074" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>; <a href="./references#CD008900-bbs2-0113" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>). We used GRADEpro GDT(<a href="./references#CD008900-bbs2-0065" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 6 August 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>). We justified all decisions to downgrade the quality of the evidence using footnotes and made comments to aid reader's understanding of the review where necessary. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008900-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008900-sec-0058"></div> <section id="CD008900-sec-0059"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD008900-sec-0103" title="">Characteristics of included studies</a>; <a href="./references#CD008900-sec-0104" title="">Characteristics of excluded studies</a>. </p> <section id="CD008900-sec-0060"> <h4 class="title">Results of the search</h4> <p>We identified a total of 39 potentially eligible records in this update. We excluded 33 references for 32 trials after full‐text screening. We incorporated 17 of these excluded studies into this update review. Six trials fulfilled our inclusion criteria. We identified no new studies for inclusion in this update. We attempted to contact authors of the included trials, but have received no response. A flow chart illustrating study selection is shown in <a href="#CD008900-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008900-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008900-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008900-sec-0061"> <h4 class="title">Included studies</h4> <p>We included six trials with a total of 597 participants in this updated review (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). </p> <p>All included studies were RCTs. Two were multicentre trials conducted in Russia, <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>, and China, <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>, while the others were a single‐centre trials. Sample sizes differed, ranging from 29 to 242 participants (each multicentre study had more than 100 participants). </p> <p>Inclusion and exclusion criteria were explicitly stated in all studies, except the Vereschagin trial (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>). Despite our attempts we could not obtain full details of this trial. Common exclusion criteria across four trials included: patients with significant concomitant neurological or psychiatric disorders; any significant systemic illness or unstable medical condition; and patients who had recently received other drugs that might impact on cognitive function (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). Relevant information of patients' exclusion was not available for the other two trials (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>). </p> <p>Two trials recruited patients with a confirmed diagnosis of VaD (both probable and possible VaD, <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>) or probable VaD, <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>, according to the NINDS‐AIREN criteria (<a href="./references#CD008900-bbs2-0108" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia. Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology1993;43:250‐60. ">Román 1993</a>); two trials, <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>, enrolled VaD patients using DSM‐IV criteria (<a href="./references#CD008900-bbs2-0045" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Press, 1994. ">APA 1994</a>); and the other trial (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>)included patients with multi‐infarct dementia based on DSM‐III‐R, <a href="./references#CD008900-bbs2-0044" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition, revised. Washington, DC: American Psychiatric Press, 1987. ">APA 1987</a>, and ICD‐10, <a href="./references#CD008900-bbs2-0124" title="World Health Organization. The 10th Revision of the International Classification of Disease and Related Health Problems (ICD‐10). Geneva: World Health Organization, 1992. ">WHO 1992</a>, criteria. All trials confirmed the VaD diagnosis using computed tomography (CT) or magnetic resonance imaging (MRI) neuroimaging scored according to the validated Hachinski ischaemic score, <a href="./references#CD008900-bbs2-0066" title="HachinskiVC , IliffLD , ZilhkaE , Du BoulayGH , McAllisterVL , MarshallJ , et al. Cerebral blood flow in dementia. Archives of Neurology1975;9:632‐7. ">Hachinski 1975</a>, or a modified version of this neuroimaging scale, <a href="./references#CD008900-bbs2-0098" title="PantoniL , InzitariD . Hachinski's ischemic score and the diagnosis of vascular dementia: a review. Italian Journal of Neurological Sciences1993;14:539‐46. ">Pantoni 1993</a>. Relevant information of VaD' diagnosis was not available for the Vereschagin trial (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>). Four trials required that baseline dementia severity be mild to moderate, as assessed using either MMSE, <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>, or Clinical Dementia Rating scores, <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>, but the range of eligible MMSE scores was not uniform (10 to 24 in <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>; 9 to 26 in <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; and 15 to 25 in <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>). The remaining two trials did not report severity of VaD. The mean age of participants in each study ranged from 60.4 to 70.8 years. Three trials described mean duration of dementia (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>), which ranged from 4.6 months to 4.3 years. </p> <p>In all the included trials, Cerebrolysin was administered as an intravenous infusion, diluted in physiologic saline or glucose injection. Four trials described comparing Cerebrolysin with placebo (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), whilst the other two trials compared Cerebrolysin with routine treatment. Routine treatments used in the trials differed and were not standard treatments recommended in international guidelines (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a> used mannitol, energy mixture, and Naomingjing; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a> used intravenous Xuesaitong). The dose of Cerebrolysin ranged from 10 mL to 30 mL daily. The length of treatment also varied amongst trials. Three studies administered the intervention five days a week and repeated for four continuous weeks as one cycle.  Using this approach, two studies treated participants for one cycle only (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>), whilst one study repeated two cycles with an interval of eight weeks between cycles (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). Two trials administered Cerebrolysin continuously for 15 days, <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>, and 28 days, <a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>. The remaining trial had the longest period of treatment with Cerebrolysin (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>), administering in cycles of 10 days, repeated for two cycles per year over three years. One study had three comparison arms (Cerebrolysin 10 mL versus 30 mL versus physiologic saline) (<a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>). </p> <p>The duration of follow‐up varied from 15 days to 3 years after enrolment. All six trials reported losses to follow‐up and withdrawals. Only one trial performed an ITT analysis based on the 'last observation carried forward' method (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). </p> <p>The most common outcome included in trials was change of cognitive function from baseline, and some form of cognitive assessment was reported in all the included trials. The scales used to quantify this change differed between trials, including MMSE, Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version (ADAS‐cog+), Hasegawa Dementia Scale (HDS), and Wechsler Adult Intelligence Scale (WAIS). In addition to multidomain tests, single‐domain tests (Trail‐Making Test A) and short screening tests (Clock‐Drawing Test) were also included in the trial outcomes. Three studies reported participant global function before and after treatment (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), evaluated by Clinician's Interview‐Based Impression of Change plus Caregiver Input (CIBIC+), Clinician's Interview‐Based Impression of Severity (CIBIS+), Activities of Daily Living (ADL), Investigator's Clinical Global Impression (CGI), Sandoz Clinical Assessment ‐ Geriatric (SCAG), or Nuremberg Activities Inventory (NAI). Four included trials reported adverse events associated with Cerebrolysin in detail (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), whilst the remaining two studies provided no relevant information (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>). None of the trials described data on quality of life or caregiver burden. </p> <p>Three trials were supported by the pharmaceutical industry (EVER Neuro Pharma GmbH) (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). One of these studies was simultaneously funded by the Society for the Study of Neuroprotection and Neuroplasticity (Romania) (<a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>). The funding of one trial was unclear (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>), although we know that the Cerebrolysin used in the trial was produced by EVER Neuro Pharma GmbH. We were unable to obtain funding information from the published paper or authors of the other two trials (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>) </p> </section> <section id="CD008900-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 32 potentially relevant studies for one or more reasons as follows: not an RCT according to the full text (<a href="./references#CD008900-bbs2-0021" title="MengL , ZhangYJ , ZhouYM . The efficacy of Cerebrolysin for 62 old patients with vascular dementia [脑活素治疗老年血管性痴呆62例疗效观察]. Journal of Mudanjiang Medical College2001;22(1):25‐6. ">Meng 2001</a>; <a href="./references#CD008900-bbs2-0012" title="DamulinIV , KoberskayaNN , MkhitaryanÉA . Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical‐electrophysiological study). Neuroscience and Behavioral Physiology2008;38(6):639‐45. ">Damulin 2008</a>; <a href="./references#CD008900-bbs2-0025" title="TapuM , BicuD , TapuF , StovicekO . The efficacy of cerebrolysin in vascular dementia. Journal of the Neurological Sciences2009;283:286. ">Tapu 2009</a>; <a href="./references#CD008900-bbs2-0024" title="SuvorovaI . Clinical efficacy of prolonged course of cerebrolysin therapy in patients with poststroke vascular dementia. New Armenian Medical Journal2010. SuvorovaI , ShprakhV . Neuroprotective therapy in basic treatment of vascular dementia. European Neuropsychopharmacology2010;20:S561. ">Suvorova 2010</a>; <a href="./references#CD008900-bbs2-0023" title="ShprakhV , SuvorovaI . Efficacy of prolonged therapy of vascular dementia [ЭФФЕКТИВНОСТЬ ДЛИТЕЛЬНОЙ ТЕРАПИИ СОСУДИСТОЙ ДЕМЕНЦИИ]. Klinicheskaia Meditsina2011;89(5):57‐60. ">Shprakh 2011</a>; <a href="./references#CD008900-bbs2-0013" title="GavrilovaSI , VolpinaOM , KolykhalovIV , FedorovaYB , SeleznevaND , PonomarevaEV , et al. Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2017;117(8):27‐38. ">Gavrilova 2017</a>); validated diagnostic criteria not used to identify patients with VaD (<a href="./references#CD008900-bbs2-0038" title="ZhengYF , XieJM , LiWD . Efficacy of cerebrolysin for vascular dementia [脑活素治疗脑血管性痴呆疗效观察]. Heilongjiang Medicine and Pharmacy1999;22(3):103. ">Zheng 1999</a>; <a href="./references#CD008900-bbs2-0008" title="CaoG , MaY . Application of Cerebrolysin in ischaemic cerebrovascular disease [脑活素在缺血性脑血管病中的合理应用]. Clinical Focus2000;21(15):986‐7. ">Cao 2000</a>; <a href="./references#CD008900-bbs2-0026" title="VereschaginNV , SuslinaZA , TimerbaevaSL , KashinaEM , GnezditskyVV , MaksimovaMY , et al. Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of randomised double blind placebo‐controlled study of cerebrolysin. Terapevticheskii Arkhiv2001;73:22‐7. ">Vereschagin 2001</a>; <a href="./references#CD008900-bbs2-0012" title="DamulinIV , KoberskayaNN , MkhitaryanÉA . Effects of Cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical‐electrophysiological study). Neuroscience and Behavioral Physiology2008;38(6):639‐45. ">Damulin 2008</a>; <a href="./references#CD008900-bbs2-0014" title="HanQS . The application value of cerebrolysin in multi‐infarction dementia [脑活素治疗多发性脑梗死性痴呆的临床应用价值评析]. Guide of China Medicine2015;13(12):189. ">Han 2015</a>; <a href="./references#CD008900-bbs2-0013" title="GavrilovaSI , VolpinaOM , KolykhalovIV , FedorovaYB , SeleznevaND , PonomarevaEV , et al. Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2017;117(8):27‐38. ">Gavrilova 2017</a>); another treatment was used in the control group but not the intervention group (<a href="./references#CD008900-bbs2-0016" title="JiaYP , ChenTW , LiYX . Application of Cerebrolysin in 30 patients of post stroke dementia [脑活素治疗卒中后痴呆30例]. New Drugs and Clinical Remedies1991;10(3):129‐30. ">Jia 1991</a>; <a href="./references#CD008900-bbs2-0017" title="LiZL , HuangW . Application of Cerebrolysin in 20 patients with vascular dementia [脑活素治疗血管性痴呆20例疗效观察]. Anhui Medicine1996;5(17):41‐2. ">Li 1996</a>; <a href="./references#CD008900-bbs2-0027" title="WangXM , SunJT , ChenHF , HanXL , HeYB . Comparative study of cytidine diphosphate choline and cerebrolysin for cerebrovascular disease and vascular dementia [胞二磷胆碱与脑活素治疗脑血管疾病和血管性痴呆疗效对比]. New Drugs and Clinical Remedies1996;15(4):244‐5. ">Wang 1996</a>; <a href="./references#CD008900-bbs2-0022" title="PanAH . Efficacy of Cerebrolysin in 20 patients with vascular dementia [脑活素治疗老年血管性痴呆20例]. Herald of Medicine1999;3(18):147. ">Pan 1999</a>; <a href="./references#CD008900-bbs2-0028" title="WangY . Efficacy of cerebrolysin in patients with multi‐infarct dementia [脑活素治疗多发性脑梗死性痴呆的临床疗效观察]. Proceeding of Clinical Medicine2003;12(5):362‐3. ">Wang 2003</a>; <a href="./references#CD008900-bbs2-0009" title="ChenH . Efficacy of Cerebrolysin for vascular dementia [脑活素治疗老年血管性痴呆疗效观察]. Chinese Journal of Practical Medicine2006;9(5):1019. ">Chen 2006</a>; <a href="./references#CD008900-bbs2-0011" title="DaiY . Efficacy of Cerebrolysin in 41 patients with vascular dementia [施普善治疗血管性痴呆41例临床疗效观察]. Chinese and Foreign Medical Research2011;15:44‐5. ">Dai 2011</a>; <a href="./references#CD008900-bbs2-0007" title="AlkebaikerJML , GuanYH , LiYB . Comparative study of citicoline and cerebrolysin for cerebrovascular disease and vascular dementia [胞磷胆碱与施普善治疗脑血管疾病和血管性痴呆疗效对比]. Chinese Journal of Hypertension2014;2(22):71‐2. ">Alkebaiker 2014</a>; <a href="./references#CD008900-bbs2-0019" title="LiuH , LiuW , FengDX . Comparative study of citicoline and cerebrolysin for patients comorbid with cerebrovascular disease and vascular dementia [用胞磷胆碱和脑活素对合并血管性痴呆的脑血管疾病患者进行治疗的效果对比]. Contemporary Medical Symposium2015;17(13):289‐90. ">Liu 2015</a>; <a href="./references#CD008900-bbs2-0029" title="WangYN . Comparative study of citicoline and cerebrolysin for cerebrovascular disease and vascular dementia [胞磷胆碱与脑活素治疗脑血管疾病和血管性痴呆的疗效对比]. Journal of Clinical Medicine2015;10(2):1836‐7. ">Wang 2015</a>; <a href="./references#CD008900-bbs2-0030" title="WangJ , ChenDX . Comparative study of citicoline and cerebrolysin for cerebrovascular disease and vascular dementia [胞磷胆碱与脑活素治疗脑血管疾病和血管性痴呆疗效对比]. For All Health2016;30(10):136. ">Wang 2016</a>; <a href="./references#CD008900-bbs2-0035" title="XueH . Comparative study of citicoline and cerebrolysin for cerebrovascular disease and vascular dementia [胞磷胆碱与脑活素治疗脑血管疾病和血管性痴呆疗效对比]. World Latest Medicine Information2016;22(16):95‐6. ">Xue 2016</a>; <a href="./references#CD008900-bbs2-0032" title="WangYC . Comparative study of citicoline and cerebrolysin for cerebrovascular disease and vascular dementia [胞磷胆碱与脑活素治疗脑血管疾病和血管性痴呆的疗效对比评价]. Inner Mongolia Medical Journal2018;50(6):678‐9. ">Wang 2018</a>); or used in the intervention group but not the control group (<a href="./references#CD008900-bbs2-0015" title="HaoGM . Comparative study of citicoline and cerebrolysin for cerebrovascular disease and vascular dementia [胞磷胆碱与脑活素治疗脑血管疾病和血管性痴呆的疗效对比]. China Continuing Medical Education2015;12(7):164‐5. ">Hao 2015</a>; <a href="./references#CD008900-bbs2-0034" title="XuJC . Jiannaoyizhi decoction combined with acupoint injection of cerebrolysin in treatment of senile vascular dementia randomized controlled study [健脑益智汤联合穴位注射脑蛋白水解物治疗老年血管性痴呆随机平行对照研究]. Journal of Practical Traditional Chinese Internal Medicine2016;12(30):85‐8. ">Xu 2016</a>; <a href="./references#CD008900-bbs2-0031" title="WangXH . Comparative study of citicoline and cerebrolysin for patients comorbid with cerebrovascular disease and vascular dementia [胞磷胆碱和脑活素对合并血管性痴呆的脑血管病患者进行治疗的效果对比评价]. Journal of Clinical Medicine2017;4(75):14804‐6. ">Wang 2017</a>); Cerebrolysin was used in both groups as a routine treatment (<a href="./references#CD008900-bbs2-0033" title="XianMJ , JiangXD , YangZ , LiCM , YuanL , FangL , et al. Effect of galanthamine on memory and quality of life in patients with vascular dementia [加兰他敏对血管性痴呆患者记忆和生活质量的影响]. Chinese Journal of Clinical Rehabilitation2004;8(16):3022‐3. ">Xian 2004</a>; <a href="./references#CD008900-bbs2-0010" title="ChenRP . Efficacy of galanthamine in patients with vascular dementia [加兰他敏对血管性痴呆患者的临床治疗效果观察]. Journal of North Pharmacy2014;8(11):72‐3. ">Chen 2014</a>; <a href="./references#CD008900-bbs2-0036" title="ZhaoJ . Efficacy of xingnaojing combined with venortuon and cerebrolysin in 60 patients with vascular dementia [醒脑静联合维脑路通及脑活素治疗血管性痴呆60例观察]. Journal of Practical Traditional Chinese Medicine2015;12(31):1134. ">Zhao 2015</a>; <a href="./references#CD008900-bbs2-0020" title="LiuQ , FuBS , ZhongYX , WangY , DingY . Oxiracetam combined with cerebroprotein hydrolysate injection for treating cognitive dysfunction after stroke and its influence on serum Hcy and hs‐CRP levels [奥拉西坦联合脑蛋白水解物治疗脑卒中后认知功能障碍的临床疗效及对血清Hcy、hs‐CRP水平的影响]. Journal of Guangxi Medical University2017;34(12):1748‐51. ">Liu 2017a</a>; <a href="./references#CD008900-bbs2-0037" title="ZhaoYM . Efficacy of Xuesaitong decoction combined with Cerebrolysin in 50 patients with poststroke dementia [自拟血塞通汤剂联合脑蛋白水解物辨治脑卒中认知功能障碍患者 50 例]. Global Traditional Chinese Medicine2017;10(1):80‐2. ">Zhao 2017</a>); study only involved a subset of participants with VaD, and the data for relevant participants could not be extracted (<a href="./references#CD008900-bbs2-0018" title="LiN , LiLW . Efficacy of cerebrolysin for elderly dementia [脑蛋白水解物注射液治疗老年期痴呆的疗效观察]. Guide of China Medicine2014;36(12):195‐9. ">Li 2014</a>); all outcomes were evaluated with invalidated scales (<a href="./references#CD008900-bbs2-0021" title="MengL , ZhangYJ , ZhouYM . The efficacy of Cerebrolysin for 62 old patients with vascular dementia [脑活素治疗老年血管性痴呆62例疗效观察]. Journal of Mudanjiang Medical College2001;22(1):25‐6. ">Meng 2001</a>). </p> </section> </section> <section id="CD008900-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>According to the summary assessment for risk of bias (<a href="./references#CD008900-bbs2-0074" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), we rated one of the trials as low risk of bias (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>); four as unclear risk of bias (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>); and one as high risk of bias (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>) (see <a href="./references#CD008900-sec-0103" title="">Characteristics of included studies</a>; <a href="#CD008900-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008900-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008900-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008900-sec-0064"> <h4 class="title">Allocation</h4> <p>All included trials stated they allocated participants to each study group randomly, but only two of them provided information about the random sequence generation (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>): <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a> used computer software to generate randomisation codes, whilst <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a> allocated participants by drawing lots. The Guekht study also specified that the random allocation sequence was concealed throughout the trial, using sealed, sequentially numbered, identical cardboard boxes containing blinded study medication according to the allocation sequence (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). Descriptions in the reports of the other trials were insufficient to permit a judgement as to whether allocation concealment was adequate (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>). </p> </section> <section id="CD008900-sec-0065"> <h4 class="title">Blinding</h4> <p>Five trials used a double‐blind design (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), of which three clearly stated that all participants and personnel involved in therapy performance and outcome assessment were blinded to treatment assignment during the entire study period (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The Xiao study (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>), reported to be double‐blind, used yellow opaque infusion bottles containing Cerebrolysin or placebo to secure blinding, which would indicate that the participants and personnel involved in treatment performance might be blinded to participant assignment, but whether the efficacy evaluators were also blinded could not be judged according to the reports. <a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a> referred to blinding method only as "double‐blind", with no other relevant information available as to who was blinded. The remaining trial was an unblinded study according to the full text (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>): Cerebrolysin was an additional medication to routine treatment for ischaemic stroke in the intervention group, whereas the control group was treated with routine treatment only without any placebo or blank solution, which made it impossible to perform blinding. </p> </section> <section id="CD008900-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>All included studies reported the duration of follow‐up. Follow‐up varied substantially between trials. Three studies followed up participants less than one month after starting treatment (15 days in <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a> and 4 weeks in <a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a> and <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>). There were no dropouts in the first two studies, whilst one participant withdrew in the third trial because of refusal of treatment (data were not included in the analyses) (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>). We found two reports of results in different phases of the <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a> trial: the pilot phase evaluated the effects of Cerebrolysin after a four‐week treatment, when there had been no participant withdrawal (<a href="./references#CD008900-bbs2-0091" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. ">Muresanu 2008b</a>); the extension study investigated efficacy outcomes through 12 weeks after the end of treatment, but eight participants (three and four in the two Cerebrolysin groups, respectively, and one in the placebo group) were lost to the follow‐up visit, with balanced numbers and reasons between groups. Data on the remaining 33 participants were assessed for the paper. The <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a> trial, with the largest sample size (242 participants in total), lost 25 participants during the 24‐week study, with similar numbers and reasons for discontinuation in the two groups. Those withdrawn were included in ITT analyses based on the 'last observation carried forward' data. Participants included in the ITT analyses had to have received at least one dose of study medication and have baseline plus at least one postbaseline assessment for both primary efficacy measures. As a result, four and six enrolled participants in each group were excluded from analysis. Although two participants were withdrawn because of adverse events, we judged the risk of attrition bias due to incomplete outcome data to be low. The sixth trial (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>), with only 29 participants in a single centre, reported no attrition over three years. </p> </section> <section id="CD008900-sec-0067"> <h4 class="title">Selective reporting</h4> <p>The study protocol was available for only one included trial (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), on ClinicalTrials.gov. All of the study's prespecified (both primary and secondary) outcome measures that were of interest in the current review were reported as per protocol, resulting in a judgement of low risk of bias due to selective reporting. We judged one trial as at high risk of bias for this domain (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>), as it did not mention the results for safety evaluation, which would be expected to have been reported as a key outcome for such an intervention study. We assessed the remaining four trials as at unclear risk of bias for this domain because protocols were unavailable and insufficient information could be obtained to make a definitive judgement(<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>). </p> </section> <section id="CD008900-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>Another potential risk of performance bias might come from a relaxed design of the intervention in the <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a> study. Participants in both groups were treated with other medicine according to their condition, but which drugs were used was not recorded. Whether these drugs were balanced between groups or would impact the results was not specified in the article. We found no other potential bias in four trials (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), and insufficient information could be obtained from the remaining trial (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>). </p> </section> </section> <section id="CD008900-sec-0069"> <h3 class="title" id="CD008900-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD008900-tbl-0001"><b>Summary of findings for the main comparison</b> Cerebrolysin for vascular dementia</a> </p> <section id="CD008900-sec-0070"> <h4 class="title">Primary outcomes</h4> <section id="CD008900-sec-0071"> <h5 class="title">Cognitive function</h5> <p>General cognitive function was evaluated as a primary efficacy parameter in all the included trials, but the instruments used and the type of data varied between trials. </p> <p>For the overall evaluation of the effect of Cerebrolysin on cognitive function, validated tools of cognitive function included MMSE, ADAS‐cog+, and WAIS. Three studies reported response rates or partial data from scales that were not detailed enough to permit inclusion in meta‐analysis (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>). We thus included 3 studies involving 420 participants, of which 223 received Cerebrolysin (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). Where more than one measure of cognitive function was used in a study, data from the most common or the most extensive measure (in all cases MMSE) were included in the meta‐analysis. </p> <p>The meta‐analysis suggested a beneficial effect of Cerebrolysin (standardised mean difference 0.36, 95% confidence interval (CI) 0.13 to 0.58; P = 0.002; <a href="./references#CD008900-fig-0012" title="">Analysis 1.1</a>; <a href="#CD008900-fig-0003">Figure 3</a>). We assessed the quality of the evidence as very low due to concerns related to imprecision, indirectness, and serious risk of bias (<a href="./full#CD008900-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD008900-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.1 Change of cognitive function measured by MMSE or ADAS‐cog+." data-id="CD008900-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.1 Change of cognitive function measured by MMSE or ADAS‐cog+. </p> </div> </div> </div> <p>Two trials with 379 participants evaluated the effect of Cerebrolysin on general cognitive function measured by the MMSE score change from baseline (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a> trial reported means but not standard deviations for change from baseline. However, the study also reported the P value (0.028) for the comparison between groups, and so we calculated the missing change‐from‐baseline standard deviation using the method described in Section 7.7.3.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008900-bbs2-0072" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). The <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a> study also used the MMSE, but only reported response rates and not raw or change scores, and so could not be included in the meta‐analysis. Previous studies reported a change in MMSE test scores of at least two to four points as indicating a reliable change at the 90% confidence level (<a href="./references#CD008900-bbs2-0069" title="HenselA , AngermeyerMC , Riedel‐HellerSG . Measuring cognitive change in older adults: reliable change indices for the Mini‐Mental State Examination. Journal of neurology, neurosurgery, and psychiatry2007;78:1298‐303. ">Hensel 2007</a>; <a href="./references#CD008900-bbs2-0117" title="SteinJ , LuppaM , MaierW , WagnerM , WolfsgruberS , SchererM , et al. Assessing cognitive changes in the elderly: reliable change indices for the Mini‐Mental State Examination. Acta psychiatrica Scandinavica2012;126:208‐18. ">Stein 2012</a>). Smaller changes may not be reliable or clinically meaningful. </p> <p>The meta‐analysis suggested a beneficial effect of Cerebrolysin on general cognitive function measured with the MMSE (mean difference (MD) 1.10, 95% CI 0.37 to 1.82; P = 0.003; <a href="./references#CD008900-fig-0013" title="">Analysis 1.2</a>; <a href="#CD008900-fig-0004">Figure 4</a>). We assessed the quality of the evidence as very low due to imprecision, indirectness, and serious risk of bias. </p> <div class="figure" id="CD008900-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.2 Change of general cognitive function measured by MMSE." data-id="CD008900-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.2 Change of general cognitive function measured by MMSE. </p> </div> </div> </div> <p>The effect on global cognitive function was also evaluated by the change of ADAS‐cog+ scores in two trials with 273 participants (<a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). ADAS‐cog+ is more sensitive in mild cognitive impairment than the original ADAS‐cog version, since it covers more cognitive domains (visual attention, executive function, and delayed recall). Impairments in these domains may be particularly relevant in people with vascular cognitive impairment (<a href="./references#CD008900-bbs2-0088" title="MohsRC , KnopmanD , PetersenRC , FerrisSH , ErnestoC , GrundmanM , et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease &amp; Associated Disorders1997;11(Suppl 2):S13‐21. ">Mohs 1997</a>). For the <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a> study, we only included data from the four‐week pilot study, although relevant outcomes were measured through a 12‐week extension, because the extension was open‐label, and nearly 20% of participants (8/41 in total; 3/16, 4/15, and 1/10 from the 10 mL Cerebrolysin, 30 mL Cerebrolysin, and placebo groups, respectively) were lost to follow‐up. We combined the two experimental intervention groups treated with different doses of Cerebrolysin into a single group using the method described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008900-bbs2-0073" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). Past studies have considered a 3‐ to 4‐point change on the ADAS‐cog to be clinically relevant (<a href="./references#CD008900-bbs2-0089" title="MolnarFJ , Man‐Son‐HingM , FergussonD . Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society2009;57:536‐46. ">Molnar 2009</a>; <a href="./references#CD008900-bbs2-0111" title="SchragA , SchottJM , Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS‐Cog?. Journal of neurology, neurosurgery, and psychiatry2012;83:171‐3. ">Schrag 2012</a>). </p> <p>The meta‐analysis suggested a beneficial effect of Cerebrolysin (MD −4.21, 95% CI −7.87 to −0.56; P = 0.02; <a href="./references#CD008900-fig-0014" title="">Analysis 1.3</a>; <a href="#CD008900-fig-0005">Figure 5</a>). We judged the quality of the evidence to be very low due to imprecision and serious risk of bias. </p> <div class="figure" id="CD008900-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.3 Change of general cognitive function measured by ADAS‐cog+ score." data-id="CD008900-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.3 Change of general cognitive function measured by ADAS‐cog+ score. </p> </div> </div> </div> <p>The authors of the <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a> trial reported WAIS scores at the end of three‐year follow‐up. Superiority of Cerebrolysin to control was reported in most of the verbal and performance subtests, including information, comprehension, arithmetic, similarities, digit span, vocabulary, digit symbol, picture completion, and picture arrangement (all P &lt; 0.05), but the full intelligence quotient (IQ) was not given or compared between groups (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>). </p> <p>In addition to continuous data, some trials presented dichotomised data describing the number of responders at a certain threshold score. For studies using the ADAS‐cog+, responders were defined as those with at least a 4‐point improvement from baseline to the end of follow‐up (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), and for the HDS and MMSE, responders were those with at least a 2‐point increase compared to baseline (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>). We pooled data on response rates from these three trials with a total of 338 participants (<a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The meta‐analysis suggested a benefit of Cerebrolysin (risk ratio (RR) 1.46, 95% CI 1.10 to 1.94; P = 0.008; <a href="./references#CD008900-fig-0015" title="">Analysis 1.4</a>; <a href="#CD008900-fig-0006">Figure 6</a>). We assessed the quality of the evidence to be very low due to concerns related to imprecision, indirectness, and serious risk of bias (<a href="./full#CD008900-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD008900-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.4 Improvement of general cognitive function reported as responder rates." data-id="CD008900-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.4 Improvement of general cognitive function reported as responder rates. </p> </div> </div> </div> <p>Two included trials evaluated executive function, one of the specific cognitive functions commonly impaired in VaD, using the Trail‐Making Test (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). Meta‐analysis suggested a beneficial effect of Cerebrolysin on time taken to complete the test (MD −24.75 s, 95% CI −40.46 to −9.03 s; P = 0.002; <a href="./references#CD008900-fig-0016" title="">Analysis 1.5</a>; <a href="#CD008900-fig-0007">Figure 7</a>). We judged the quality of the evidence to be very low due to concerns related to imprecision, indirectness, and serious risk of bias. </p> <div class="figure" id="CD008900-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.5 Change of executive function measured by the Trail‐Making Test." data-id="CD008900-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.5 Change of executive function measured by the Trail‐Making Test. </p> </div> </div> </div> <p>One trial used the Clock‐Drawing Test (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The authors reported a beneficial effect of Cerebrolysin of 0.92 points (95% CI 0.45 to 1.39; P&lt;0.001). We judged the quality of the evidence to be low due to concerns related to imprecision and indirectness.  </p> <p>The remaining trial stated that Cerebrolysin treatment resulted in significant improvements in memory, abstract thinking, and reaction time, confirmed by EEG‐mapping, but detailed data were unavailable for any outcomes to permit inclusion in meta‐analysis (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>). </p> </section> <section id="CD008900-sec-0072"> <h5 class="title">Global function</h5> <p>Improvement in global function was reported as response rates in two trials: in one trial investigators used the CIBIC+ scale (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), and CGI was used in the other trial (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>). For pooled analysis, we defined responders as those with a CIBIC+ score of &lt; 3 or those judged as at least moderately improved using the CGI rating at the last visit. The meta‐analysis suggested a benefit of Cerebrolysin (RR 2.69, 95% CI 1.82 to 3.98; P&lt;0.001; <a href="./references#CD008900-fig-0017" title="">Analysis 2.1</a>; <a href="#CD008900-fig-0008">Figure 8</a>). We assessed the quality of the evidence as very low due to concerns related to imprecision, indirectness, and serious risk of bias. (<a href="./full#CD008900-tbl-0001">summary of findings Table for the main comparison</a>) </p> <div class="figure" id="CD008900-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Global function, outcome: 2.1 Improvement of global function reported as responder rates." data-id="CD008900-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Global function, outcome: 2.1 Improvement of global function reported as responder rates. </p> </div> </div> </div> <p>Change in global functional performance was measured by various scales across two included trials (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The scales measured different constructs and were not considered suitable for meta‐analysis. In one trial, there was a beneficial effect of Cerebrolysin on ADL measures (MD 6.32, 95% CI 4.20 to 8.45; P&lt;0.001; <a href="./references#CD008900-fig-0018" title="">Analysis 2.2</a>; <a href="#CD008900-fig-0009">Figure 9</a>) (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). We judged the quality of the evidence to be low due to imprecision and indirectness. The other study used various scales and found no effect on global function for any measure (ADL: MD 0.77, 95% CI −0.93 to 2.47, P = 0.38; NAI: MD −0.75, 95% CI −2.33 to 0.83, P = 0.35; SCAG: MD −0.45, 95% CI −3.42 to 2.52, P = 0.77) (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>). We judged the quality of the evidence to be very low due to concerns related to imprecision, indirectness, and serious risk of bias. </p> <div class="figure" id="CD008900-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Global function, outcome: 2.2 Change of global function measured by ADCS‐ADL score." data-id="CD008900-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Global function, outcome: 2.2 Change of global function measured by ADCS‐ADL score. </p> </div> </div> </div> </section> <section id="CD008900-sec-0073"> <h5 class="title">All‐cause death</h5> <p>Only one trial reported mortality and specified that no deaths were reported during the experimental and follow‐up periods (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). No specific data on all‐cause mortality were available from the other included trials, although three trials reported no severe adverse effects in either group (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>). We judged the quality of the evidence to be very low due to concerns related to imprecision, indirectness, and serious risk of bias. </p> </section> </section> <section id="CD008900-sec-0074"> <h4 class="title">Secondary outcomes</h4> <section id="CD008900-sec-0075"> <h5 class="title">Adverse events</h5> <p>Adverse events were categorised as 'serious' or 'not serious'. Serious adverse events were those that led to death; were life‐threatening; required inpatient hospitalisation or prolongation of existing hospitalisation; resulted in persistent or significant disability; or was any important medical event that might have jeopardised the participant or required intervention to prevent it. All other adverse events were considered to be non‐serious (<a href="./references#CD008900-bbs2-0076" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. International Digest of Health Legislation1997;48:231‐4. ">ICHEWG 1997</a>). </p> <p>Four included trials assessed safety by a mix of reporting adverse events, performing physical examinations or laboratory tests (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The relationship between adverse events and Cerebrolysin therapy was judged by investigators. The remaining two trials did not mention adverse events (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>). </p> <p>Three serious adverse events occurred during the <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a> trial: acute pyelonephritis, malignant lung neoplasm, and rectosigmoid cancer (3/117 and 0/115 in the Cerebrolysin and placebo groups, respectively).  The adverse events were considered to be unrelated to the experimental treatment, and there was no significant difference between groups (RR 6.88, 95% CI 0.36 to 131.75; P = 0.20; <a href="./references#CD008900-fig-0019" title="">Analysis 3.1</a>; <a href="#CD008900-fig-0010">Figure 10</a>). We assessed the quality of the evidence to be low due to concerns related to imprecision and indirectness. Three included trials reported no severe adverse effects in either group (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>). We judged the quality of the evidence to be very low due to concerns related to imprecision, indirectness, and serious risk of bias. </p> <div class="figure" id="CD008900-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Adverse events, outcome: 3.1 Serious adverse events." data-id="CD008900-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Adverse events, outcome: 3.1 Serious adverse events.</p> </div> </div> </div> <p>The most commonly reported non‐serious adverse events were headache, asthenia, dizziness, hypertension, and hypotension. Two trials provided sufficient data on adverse events by treatment arm to permit meta‐analysis (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). The meta‐analysis suggested no difference between groups in rates of adverse events (RR 0.91, 95% CI 0.29 to 2.85; P = 0.87; <a href="./references#CD008900-fig-0020" title="">Analysis 3.2</a>; <a href="#CD008900-fig-0011">Figure 11</a>). We judged the quality of the evidence as very low due to concerns related to imprecision, indirectness, and serious risk of bias (<a href="./full#CD008900-tbl-0001">summary of findings Table for the main comparison</a>). The <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a> trial also reported withdrawals due to adverse events, which were balanced between groups (1.7% for the Cerebrolysin group and 2.5% for the control group, P = 0.67) (<a href="./references#CD008900-fig-0021" title="">Analysis 3.3</a>). The <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a> trial only stated that no severe adverse events had occurred, and no significant differences in non‐serious adverse events were found between groups, but relevant quantitative data were unavailable. Zhang and colleagues specified that no non‐serious adverse events were found during the three‐year experimental period (<a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>). </p> <div class="figure" id="CD008900-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Adverse events, outcome: 4.1 Non‐serious adverse events." data-id="CD008900-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Adverse events, outcome: 4.1 Non‐serious adverse events.</p> </div> </div> </div> <p>The <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a> and <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a> trials also reported the change in laboratory parameters, including haematology, clinical chemistry, urinalysis, and electrocardiogram, and revealed no relevant differences between groups. </p> </section> <section id="CD008900-sec-0076"> <h5 class="title">Quality of life</h5> <p>No data on quality of life during the treatment and follow‐up periods were available from any of the included trials (<a href="./full#CD008900-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD008900-sec-0077"> <h5 class="title">Caregiver burden</h5> <p>No data on evaluation of caregiver burden were available from any of the included trials (<a href="./full#CD008900-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD008900-sec-0078"> <h4 class="title">Subgroup analyses</h4> <p>Significant statistical heterogeneity was present in the analysis of change in ADAS‐cog+ score (<a href="./references#CD008900-fig-0014" title="">Analysis 1.3</a>, I<sup>2</sup> = 86%) and the analysis of rates of non‐serious adverse events (<a href="./references#CD008900-fig-0020" title="">Analysis 3.2</a>, I<sup>2</sup> = 59%). Treatment duration differed between these and other studies, which could plausibly explain differential results. We were not able to perform a meta‐regression of treatment effect against the duration of intervention as the number of included trials was too small. We therefore undertook subgroup analyses defining categories of short‐ and longer‐term treatment duration. </p> <section id="CD008900-sec-0079"> <h5 class="title">Short‐term treatment duration (defined as only one treatment cycle or four weeks or less of treatment) </h5> <p>In four included trials, Cerebrolysin was given to participants for only one treatment cycle (five days a week repeated for four weeks), <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>, or four continuous weeks or less, <a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>. There was a beneficial effect of short‐term treatment with Cerebrolysin on general cognitive function measured by MMSE score in one study (MD 0.96, 95% CI 0.12 to 1.80; P = 0.03; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0022" title="">Analysis 4.1</a>) and ADAS‐cog+ in one study (MD −2.38, 95% CI −4.18 to −0.58; P = 0.01; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0023" title="">Analysis 4.2</a>). However, a continuous 15‐day treatment with Cerebrolysin had no effect on the response rate as measured by the HDS (RR 1.22, 95% CI 1.00 to 1.50; P = 0.05; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0024" title="">Analysis 4.3</a>). In one study, Cerebrolysin had a beneficial effect on CGI after one cycle of treatment (RR 2.18, 95% CI 1.16 to 4.10; P = 0.02; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0025" title="">Analysis 4.4</a>). The same study reported non‐serious side effects and found no difference between groups (RR 0.48, 95% CI 0.15 to 1.52; P = 0.21; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0026" title="">Analysis 4.5</a>). </p> </section> <section id="CD008900-sec-0080"> <h5 class="title">Longer treatment duration (defined as two or more treatment cycles or more than four weeks treatment) </h5> <p>Two trials had a longer treatment duration of 24 weeks, <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>, and three years, <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>. Cerebrolysin had a beneficial effect on MMSE (MD 1.48, 95% CI 0.06 to 2.91; P = 0.04; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0022" title="">Analysis 4.1</a>), and a beneficial effect on ADAS‐cog+ (MD −6.11, 95% CI −8.16 to −4.06; P &lt; 0.001; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0023" title="">Analysis 4.2</a>) and responder rates (RR 1.66, 95% CI 1.23 to 2.24; P = 0.001; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0024" title="">Analysis 4.3</a>). Two cycles of treatment with Cerebrolysin over 24 weeks also had a beneficial effect on clinically assessed global function (RR 3.07, 95% CI 1.86 to 5.07; P &lt; 0.001; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0025" title="">Analysis 4.4</a>). Longer‐term treatment resulted in no difference in the occurrence of non‐serious adverse events (RR 1.54, 95% CI 0.62 to 3.84; P = 0.35; very low‐quality evidence due to concerns related to imprecision, indirectness, and serious risk of bias; <a href="./references#CD008900-fig-0026" title="">Analysis 4.5</a>). </p> </section> </section> <section id="CD008900-sec-0081"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses based on 'Risk of bias' assessment, limiting to those studies at low risk of bias. Since only one included study was rated as at low risk of bias (<a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), we repeated our analyses limited to data from this study. The overall results were unchanged (<a href="./references#CD008900-fig-0027" title="">Analysis 5.1</a>; <a href="./references#CD008900-fig-0028" title="">Analysis 5.2</a>; <a href="./references#CD008900-fig-0029" title="">Analysis 5.3</a>; <a href="./references#CD008900-fig-0030" title="">Analysis 5.4</a>; <a href="./references#CD008900-fig-0031" title="">Analysis 5.5</a>; <a href="./references#CD008900-fig-0032" title="">Analysis 5.6</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008900-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008900-sec-0082"></div> <section id="CD008900-sec-0083"> <h3 class="title" id="CD008900-sec-0083">Summary of main results</h3> <p>We found six eligible and relevant RCTs evaluating the efficacy of Cerebrolysin for VaD (<a href="./references#CD008900-bbs2-0004" title="VereschaginNV , NekrasovaYM , LebedevaNV , SuslinaZA , SolovyevOI , PiradovMA , et al. Mild forms of multi‐infarct dementia ‐ effectiveness of Cerebrolysin. Sovetskaya Meditsina1991;11:6‐8. ">Vereschagin 1991</a>; <a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>), with five trials providing full data suitable for meta‐analysis (<a href="./references#CD008900-bbs2-0005" title="XiaoS , YanH , YaoP . The efficacy of Cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double‐blind, placebo‐controlled trial. Hong Kong Journal of Psychiatry1999;9(2):13‐9. XiaoS , YanH , YaoPF , WanglN , TangHC , JiaJJ , et al. A multi‐center, double blind, placebo‐controlled trial of the efficacy of Cerebrolysin in treatment of vascular dementia. Journal of Clinical Psychological Medicine1999;9(1):1‐3. ">Xiao 1999</a>; <a href="./references#CD008900-bbs2-0002" title="LiangSY , LiZJ , YanHJ , PeiXM . The efficacy of Cerebrolysin in multi‐infarct dementia [脑活素治疗多发性脑梗塞性痴呆的疗效观察]. Heilongjiang Medicine and Pharmacy2001;24(5):75. ">Liang 2001</a>; <a href="./references#CD008900-bbs2-0006" title="ZhangLJ , PanXH , WangYH , ShengHT . Cerebrolysin improves the intelligence of vascular dementia patients in clinic [脑活素改善血管性痴呆患者智能状况的临床研究]. Chinese Journal of Clinical Rehabilitation2003;7(28):3850‐1. ">Zhang 2003</a>; <a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0001" title="GuekhtA , DopplerE , MoesslerH , GusevE . Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: results from a randomized, double‐blind, placebo‐controlled, multicenter trial. European Journal of Neurology2009;16 (Suppl 3):391. GuekhtAB , MoesslerH , NovakPH , GusevEI . Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double‐blind, placebo‐controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases2011;20(4):310‐8. NCT00947531 . A clinical trial to evaluate the safety and efficacy of 20 ml Cerebrolysin in patients with Vascular Dementia (VascDem). clinicaltrials.gov/ct2/show/study/NCT00947531 Date first received: 28 July 2009. ">Guekht 2011</a>). No new studies were eligible for inclusion for this update. </p> <p>Based on our summary data, Cerebrolysin may improve cognitive and general function with few adverse effects in people living with VaD. Beneficial effects on cognitive function were consistent across various assessment scales and various methods of analysing these data. Benefits were seen in both global cognitive function and in specific aspects of cognition said to be more impaired in VaD, namely executive function. However, there were substantial limitations in the published studies, and these data are not definitive evidence of efficacy or safety. </p> <p>The summary effect sizes reported were often smaller than what is considered the minimal important clinical difference for the relevant scale. This may relate in part to the relatively short length of follow‐up across most of the studies. If the effect of Cerebrolysin is to slow the cognitive decline of VaD, it would be surprising to see clinically important differences in cognitive scores with studies that follow‐up participants for weeks only. </p> <p>There were substantial differences in terms of dosage, frequency, and duration of administration of Cerebrolysin. We were able to perform a subgroup analysis that suggested increased benefit with longer duration of therapy. This result is not based on direct comparisons of differing treatment regimens and so must be interpreted with caution. Our review does not permit a recommendation for the optimum treatment schedule. </p> <p>There is a degree of treatment burden associated with Cerebrolysin administration. Treatment requires frequent intravenous infusions in the hospital setting. We thought that assessing quality of life of both people living with vascular dementia and their caregivers would be important, but no studies reported these outcomes. </p> </section> <section id="CD008900-sec-0084"> <h3 class="title" id="CD008900-sec-0084">Overall completeness and applicability of evidence</h3> <p>Most included studies had data relevant to our prespecified outcomes of interest. However, reporting was often poor, and we could not always use these data in summary analyses. There were no data on quality of life despite the importance of this outcome to people living with dementia and their caregivers. </p> <p>The study participants were representative of a population of adults with mild to moderate VaD. Ages were younger than would be seen in a contemporary, unselected vascular dementia cohort. Various pathologies were included under the vascular dementia rubric. Data were insufficient to draw any conclusions about differential effect based on subtype of VaD. </p> <p>The studies were mostly from Eastern Europe and China, and some of the studies were rather old. Dementia care differs across international settings, and some of the treatments used as routine in the included studies are not recommended in European or North American guidelines. Best practice in dementia care has also changed over time, and the generalisability of studies that are decades old is also questionable. </p> </section> <section id="CD008900-sec-0085"> <h3 class="title" id="CD008900-sec-0085">Quality of the evidence</h3> <p>We assessed only one study as at low risk of bias. Issues common to the other included studies, such as lack of a published protocol, may reflect the historical nature of these trials. A registered protocol would now be mandatory for any published RCT of an interventional medicinal product. Reporting of study conduct was poor, and we had to assess several domains as unclear risk of bias. Again, the included studies pre‐date the era of mandatory use of reporting guidelines and checklists. Such reporting omissions should now be less frequent. Where details were not reported, such as for randomisation or allocation concealment, it seems likely that these aspects of good trial practice were not adhered to and that an overall assessment of high risk of bias could be made. </p> <p>Applying the GRADE framework, we assessed the strength of evidence as low or very low. Issues related to risk of bias were common across the studies and represented a serious threat to the validity of the results. The dementia care provided as comparator was not always consistent with contemporary, guideline‐based best care, and so there were issues with indirectness. Sample sizes were modest, with corresponding wide confidence intervals suggesting lack of precision. The small number of studies did not permit us to assess publication bias detailed in our protocol. With a review of a commonly used intervention, where there are few studies and all are positive despite small numbers, the potential for publication bias remains. </p> </section> <section id="CD008900-sec-0086"> <h3 class="title" id="CD008900-sec-0086">Potential biases in the review process</h3> <p>We aimed for a comprehensive search, including published and unpublished studies. Recognising the international use of Cerebrolysin, we applied no language restrictions; searched Chinese language databases; and contacted investigators and industry as required to obtain additional information. However, we were unable to obtain further data from the authors or medical companies, and it remains possible that important studies were missed. </p> <p>The small number of studies did not permit many of our planned subgroup and sensitivity analyses, and questions around patient selection and optimal treatment schedule remain. </p> </section> <section id="CD008900-sec-0087"> <h3 class="title" id="CD008900-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>Our review provides a summary of the clinical evidence regarding Cerebrolysin in VaD. A number of non‐systematic reviews describing Cerebrolysin in VaD are available (<a href="./references#CD008900-bbs2-0101" title="PloskerGL ,  GauthierS . Cerebrolysin: a review of its use in dementia. Drugs and Aging2009;26(11):893‐915. ">Plosker 2009</a>; <a href="./references#CD008900-bbs2-0102" title="PloskerGL ,  GauthierS . Spotlight on cerebrolysin in dementia. CNS Drugs2010;24(3):263‐6. ">Plosker 2010</a>; <a href="./references#CD008900-bbs2-0042" title="AllegriRF , GuekhtA . Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs of Today2012;48 Suppl A:25‐41. ">Allegri 2012</a>). Most have concluded that Cerebrolysin appears to be a well‐tolerated and effective treatment option for VaD. Given our comprehensive and systematic literature search and robust quality assessment, we believe our review is a less biased synthesis of the clinical data than these other narrative reviews. </p> <p>There are many pre‐clinical studies suggesting efficacy of Cerebrolysin in animal models of VaD (<a href="./references#CD008900-bbs2-0116" title="Solis‐GasparC , Vazquez‐RoqueRA , DeJesús Gómez‐VillalobosM , FloresG . Cerebrolysin improves memory and ameliorates neuronal atrophy in spontaneously hypertensive, aged rats. Synapse2016;70(9):378‐89. ">Solis‐Gaspar 2016</a>; <a href="./references#CD008900-bbs2-0085" title="LiuZ , HuM , LuP , WangH , QiQ , XuJ , et al. Cerebrolysin alleviates cognitive deficits induced by chronic cerebral hypoperfusion by increasing the levels of plasticity‐related proteins and decreasing the levels of apoptosis‐related proteins in the rat hippocampus. Neuroscience letters2017;651:72‐8. ">Liu 2017b</a>). However, translating pre‐clinical benefits to clinical dementia trials is often difficult (<a href="./references#CD008900-bbs2-0079" title="IOM (Institute of Medicine). Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. Washington, DC: The National Academies Press, 2013. ">IOM 2013</a>; <a href="./references#CD008900-bbs2-0047" title="BanikA , BrownRE , BamburgJ , LahiriDK , KhuranaD , FriedlandRP , et al. Translation of pre‐clinical studies into successful clinical trials for alzheimer's disease: what are the roadblocks and how can they be overcome?. Journal of Alzheimer's Disease2015;47(4):815‐43. ">Banik 2015</a>), and these data must be interpreted with caution. </p> <p>Our interest was direct clinical outcomes. There are studies that have used surrogate outcomes and found a beneficial effect of Cerebrolysin in VaD. For example, electroencephalogram (EEG) has been suggested as a potential outcome marker in VaD (<a href="./references#CD008900-bbs2-0103" title="RennaM , HandyJ , ShahA . Low baseline Bispectral Index of the electroencephalogram in patients with dementia. Anesthesia and Analgesia2003;96(5):1380‐5. ">Renna 2003</a>). Trials have demonstrated patterns of EEG activity that suggest beneficial effects of Cerebrolysin in VaD (<a href="./references#CD008900-bbs2-0003" title="MuresanuDF , AlvarezXA , MoesslerH , BuiaM , StanA , PinteaD , et al. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration. Journal of the Neurological Sciences2008;267(1‐2):112‐9. MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2008a</a>; <a href="./references#CD008900-bbs2-0092" title="MuresanuDF , AlvarezXA , MoesslerH , NovakPH , StanA , BuzoianuA , et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3‐month extension study. Journal of the Neurological Sciences2010;299(1‐2):179‐83. ">Muresanu 2010</a>). Again, whilst encouraging, these surrogate biomarkers are not sufficient to prove the benefits of a dementia treatment. </p> <p>Data from other studies and reviews have suggested positive clinical effects and good tolerability of Cerebrolysin in the treatment of AD (<a href="./references#CD008900-bbs2-0123" title="WeiZH , HeQB , WangH , SuBH , ChenHZ . Meta‐analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Journal of Neural Transmission2007;114(5):629‐34. ">Wei 2007</a>; <a href="./references#CD008900-bbs2-0135" title="ÁlvarezXA , CacabelosR , SampedroC , AleixandreM , LinaresC , GranizoE , et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double‐blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology2011;18(1):59‐68. ">Álvarez 2011a</a>; <a href="./references#CD008900-bbs2-0136" title="ÁlvarezXA , FuentesP . Cerebrolysin in Alzheimer's disease. Drugs Today (Barc)2011;47(7):487‐513. ">Álvarez 2011b</a>), albeit with many of the limitations in the quality of evidence reported in this review. The distinction between AD and VaD is not always clear‐cut, and in older adults mixed pathologies are frequent (<a href="./references#CD008900-bbs2-0057" title="ChuiHC , Ramirez‐GomezL . Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimer's research &amp; therapy2015;7(1):21. ">Chui 2015</a>). If Cerebrolysin can be shown to provide benefit in AD, an effect in VaD would seem likely. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008900-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008900-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008900-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.1 Change of cognitive function measured by MMSE or ADAS‐cog+." data-id="CD008900-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.1 Change of cognitive function measured by MMSE or ADAS‐cog+. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.2 Change of general cognitive function measured by MMSE." data-id="CD008900-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.2 Change of general cognitive function measured by MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.3 Change of general cognitive function measured by ADAS‐cog+ score." data-id="CD008900-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.3 Change of general cognitive function measured by ADAS‐cog+ score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.4 Improvement of general cognitive function reported as responder rates." data-id="CD008900-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.4 Improvement of general cognitive function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Cognitive function, outcome: 1.5 Change of executive function measured by the Trail‐Making Test." data-id="CD008900-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Cognitive function, outcome: 1.5 Change of executive function measured by the Trail‐Making Test. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Global function, outcome: 2.1 Improvement of global function reported as responder rates." data-id="CD008900-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Global function, outcome: 2.1 Improvement of global function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Global function, outcome: 2.2 Change of global function measured by ADCS‐ADL score." data-id="CD008900-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Global function, outcome: 2.2 Change of global function measured by ADCS‐ADL score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Adverse events, outcome: 3.1 Serious adverse events." data-id="CD008900-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Adverse events, outcome: 3.1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Adverse events, outcome: 4.1 Non‐serious adverse events." data-id="CD008900-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Adverse events, outcome: 4.1 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cognitive function, Outcome 1 Change of cognitive function measured by MMSE or ADAS‐cog+." data-id="CD008900-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Cognitive function, Outcome 1 Change of cognitive function measured by MMSE or ADAS‐cog+. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cognitive function, Outcome 2 Change of general cognitive function measured by MMSE." data-id="CD008900-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Cognitive function, Outcome 2 Change of general cognitive function measured by MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cognitive function, Outcome 3 Change of general cognitive function measured by ADAS‐cog+ score." data-id="CD008900-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Cognitive function, Outcome 3 Change of general cognitive function measured by ADAS‐cog+ score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cognitive function, Outcome 4 Improvement of general cognitive function reported as responder rates." data-id="CD008900-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Cognitive function, Outcome 4 Improvement of general cognitive function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cognitive function, Outcome 5 Change of executive function measured by the Trail‐Making Test." data-id="CD008900-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Cognitive function, Outcome 5 Change of executive function measured by the Trail‐Making Test. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Global function, Outcome 1 Improvement of global function reported as responder rates." data-id="CD008900-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Global function, Outcome 1 Improvement of global function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Global function, Outcome 2 Change of global function measured by ADCS‐ADL score." data-id="CD008900-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Global function, Outcome 2 Change of global function measured by ADCS‐ADL score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 1 Serious adverse events." data-id="CD008900-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 1 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 2 Non‐serious adverse events." data-id="CD008900-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 2 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 3 Withdrawals due to adverse events." data-id="CD008900-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 3 Withdrawals due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses  , Outcome 1 Change of general cognitive function measured by MMSE." data-id="CD008900-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses  , Outcome 1 Change of general cognitive function measured by MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses  , Outcome 2 Change of general cognitive function measured by ADAS‐cog+ score." data-id="CD008900-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses  , Outcome 2 Change of general cognitive function measured by ADAS‐cog+ score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses  , Outcome 3 Improvement of general cognitive function reported as responder rates." data-id="CD008900-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses  , Outcome 3 Improvement of general cognitive function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses  , Outcome 4 Improvement of global function reported as responder rates." data-id="CD008900-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses  , Outcome 4 Improvement of global function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses  , Outcome 5 Non‐serious adverse events." data-id="CD008900-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses  , Outcome 5 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 1 Change of general cognitive function measured by MMSE." data-id="CD008900-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 1 Change of general cognitive function measured by MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 2 Change of general cognitive function measured by ADAS‐cog+ score." data-id="CD008900-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 2 Change of general cognitive function measured by ADAS‐cog+ score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 3 Improvement of general cognitive function reported as responder rates." data-id="CD008900-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 3 Improvement of general cognitive function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 4 Change of executive function measured by the Trail‐Making Test." data-id="CD008900-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 4 Change of executive function measured by the Trail‐Making Test. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 5 Improvement of global function reported as responder rates." data-id="CD008900-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 5 Improvement of global function reported as responder rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008900-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/urn:x-wiley:14651858:media:CD008900:CD008900-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_t/tCD008900-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses, Outcome 6 Non‐serious adverse events." data-id="CD008900-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses, Outcome 6 Non‐serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/media/CDSR/CD008900/image_n/nCD008900-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008900-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Cerebrolysin for vascular dementia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cerebrolysin for vascular dementia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> vascular dementia<br/> <b>Setting:</b> hospitals and clinics<br/> <b>Intervention:</b> Cerebrolysin<br/> <b>Comparison:</b> placebo or routine treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Continuous outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score with placebo<br/> (mean)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mean improvement<br/> in change score<br/> between<br/> Cerebrolysin and<br/> placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>SMD (95%<br/> CI) meta‐analysis<br/> findings</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function</p> <p>(MMSE or ADAS‐cog+)<br/> follow‐up: 4 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean MMSE<br/> score at baseline<br/> was 19.9.<br/> Mean change from baseline of MMSE was 2.6. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.1 higher<br/> (0.37 higher to 1.82 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36 (0.13 to 0.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Analysed as</p> <p>standardised mean difference</p> <p>(<a href="./references#CD008900-fig-0012" title="">Analysis 1.1</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data on quality of life during the treatment and follow‐up periods were available from any of the included trials. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Caregiver burden</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data on evaluation of caregiver burden were available from the included trials.</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Binary outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or routine treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Cerebrolysin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in cognitive function reported as responder rates</p> <p>(MMSE, ADAS‐cog+, and HDS)<br/> follow‐up: 15 days to 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>554 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>809 per 1000<br/> (610 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.46<br/> (1.10 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR and control group risk from 3 studies (<a href="./references#CD008900-fig-0015" title="">Analysis 1.4</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in global function reported as response rates</p> <p>(CIBIC+ and CGI)<br/> follow‐up: 4 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>388 per 1000<br/> (263 to 575) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.69<br/> (1.82 to 3.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>379<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR and control group risk from 2 studies (<a href="./references#CD008900-fig-0017" title="">Analysis 2.1</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events<br/> follow‐up: 4 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (23 to 229) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/> (0.29 to 2.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>379<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR and control group risk from 2 studies (<a href="./references#CD008900-fig-0020" title="">Analysis 3.2</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>ADAS‐cog+:</b> Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version; <b>CGI:</b> Clinical Global Impression; <b>CI:</b> confidence interval; <b>CIBIC+:</b> Clinician's Interview‐Based Impression of Change plus Caregiver Input; <b>HDS:</b> Hasegawa Dementia Scale; <b>MD:</b> mean difference; <b>MMSE:</b> Mini‐Mental State Examination; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level due to serious concern about indirectness: the dementia care provided as comparator was not always consistent with contemporary, guideline‐based best care and so there were issues with indirectness.<br/> <sup>2</sup>Downgraded two levels due to very serious concern about risk of bias: two of the trials were at unclear risk of selection bias and unclear risk of reporting bias, and one trial was at unclear risk of detection bias. Most of the 'Risk of bias' judgements were unclear risk of bias.<br/> <sup>3</sup>Downgraded one level due to serious concern about imprecision: modest sample size.<br/> <sup>4</sup>Downgraded two levels due to very serious concern about risk of bias: two of the trials were at unclear risk of selection bias; one trial was at unclear risk of reporting bias; one trial was at unclear of other bias; one trial was at high risk of performance bias, high risk of detection bias, and high risk of reporting bias. There was a substantial risk of bias across the body of evidence.<br/> <sup>5</sup>Downgraded one level due to serious concern about imprecision: modest sample size and few events.<br/> <sup>6</sup>Downgraded two levels due to very serious concern about risk of bias: one of the trials was at unclear risk of selection bias, unclear risk of detection bias, and unclear risk of reporting bias. Most of the 'Risk of bias' judgements were unclear risk of bias.<br/> <sup>7</sup>Downgraded one level due to serious concern about imprecision: modest sample size and wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Cerebrolysin for vascular dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/full#CD008900-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008900-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cognitive function</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change of cognitive function measured by MMSE or ADAS‐cog+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.13, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change of general cognitive function measured by MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.37, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change of general cognitive function measured by ADAS‐cog+ score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.21 [‐7.87, ‐0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement of general cognitive function reported as responder rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.10, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change of executive function measured by the Trail‐Making Test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐24.75 [‐40.46, ‐9.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cognitive function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008900-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Global function</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement of global function reported as responder rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.82, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change of global function measured by ADCS‐ADL score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.32 [4.20, 8.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Global function</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008900-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.88 [0.36, 131.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.29, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.25, 8.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008900-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analyses  </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change of general cognitive function measured by MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.37, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.12, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.06, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change of general cognitive function measured by ADAS‐cog+ score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>273</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.21 [‐7.87, ‐0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.38 [‐4.18, ‐0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.11 [‐8.16, ‐4.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement of general cognitive function reported as responder rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.10, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Short‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.00, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Long‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.23, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Improvement of global function reported as responder rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.82, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Short‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [1.16, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Long‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [1.86, 5.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.29, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Short‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Long‐term treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.62, 3.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analyses  </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008900-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change of general cognitive function measured by MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.06, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change of general cognitive function measured by ADAS‐cog+ score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.11 [‐8.16, ‐4.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement of general cognitive function reported as responder rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.29, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change of executive function measured by the Trail‐Making Test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.31 [‐30.19, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Improvement of global function reported as responder rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [1.86, 5.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.62, 3.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008900.pub3/references#CD008900-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008900.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008900-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008900-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008900-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008900-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008900-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008900-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008900-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD008900-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008900\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008900\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008900\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008900\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008900\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008900.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008900.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008900.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008900.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008900.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725080188"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008900.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725080192"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008900.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e72809ed41bdf',t:'MTc0MDcyNTA4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 